var title_f39_28_40384="GEJ after therapy";
var content_f39_28_40384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The \"Stretta\" procedure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing multiple thermal lesions within the smooth muscle of gastroesophageal junction after therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George Triadafilopoulos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40384=[""].join("\n");
var outline_f39_28_40384=null;
var title_f39_28_40385="HSV lip";
var content_f39_28_40385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes simplex virus lesion on the lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40385=[""].join("\n");
var outline_f39_28_40385=null;
var title_f39_28_40386="Patient information: Lymphoma (The Basics)";
var content_f39_28_40386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15492\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/6/25702\">",
"         Lymphatic system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/50/31523\">",
"         Patient information: Hodgkin lymphoma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/60/27588\">",
"         Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/9/8339\">",
"         Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/37/13908\">",
"         Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lymphoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lymphoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H541280772\">",
"      <span class=\"h1\">",
"       What is lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lymphoma is a cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make and store cells that fight infection (",
"      <a class=\"graphic graphic_figure graphicRef63854 \" href=\"mobipreview.htm?25/6/25702\">",
"       figure 1",
"      </a>",
"      ). These infection-fighting cells are also called &ldquo;white blood cells.&rdquo;",
"     </p>",
"     <p>",
"      When people have lymphoma, their white blood cells become abnormal and grow out of control. These cells can travel to different parts of the body. Often, the abnormal cells collect in bean-shaped organs called lymph nodes. This causes the lymph nodes to swell.",
"     </p>",
"     <p>",
"      There are different types of lymphoma. Some types grow very slowly. Other types grow much faster. Sometimes, people start out with a slow-growing type of lymphoma that later becomes fast-growing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H541280779\">",
"      <span class=\"h1\">",
"       What are the symptoms of lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The first sign of lymphoma is often one or more large, swollen lymph nodes. These swollen lymph nodes can be felt under the skin, but are usually not painful. They are often in the neck, groin, armpit, or stomach.",
"     </p>",
"     <p>",
"      Lymph nodes deeper in the body can also become swollen and cause symptoms. For example, swollen lymph nodes around the lungs can cause a cough or trouble breathing.",
"     </p>",
"     <p>",
"      Other symptoms of lymphoma include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Night sweats that soak your clothes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not lymphoma. But if you have these symptoms, you should let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H541280786\">",
"      <span class=\"h1\">",
"       Is there a test for lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and ask about your symptoms. He or she might order other tests, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lymph node biopsy &ndash; A doctor will remove all or part of the swollen lymph node. Another doctor will look at cells from the lymph node under a microscope to see if cancer is present.",
"       </li>",
"       <li>",
"        Bone marrow biopsy &ndash; A doctor will take a small sample of bone marrow, which is the spongy tissue in the center of some bones. Another doctor will look at the sample under a microscope to see if it has cancer.",
"       </li>",
"       <li>",
"        Other biopsy &ndash; A doctor might remove a small sample of other abnormal tissues in the body. These samples are also checked under a microscope for cancer.",
"       </li>",
"       <li>",
"        CT scan, PET scan, or other imaging tests &ndash; These tests create pictures of the inside of your body and can show abnormal growths.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H541280793\">",
"      <span class=\"h1\">",
"       What is lymphoma staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lymphoma staging is a way in which doctors find out how far lymphoma has spread within the lymphatic system or within the body.",
"     </p>",
"     <p>",
"      The right treatment for you will depend, in part, on the stage of your lymphoma. Your treatment will also depend on the type of lymphoma you have, your age, and your other health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H541280800\">",
"      <span class=\"h1\">",
"       How is lymphoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can treat lymphoma in different ways. People with some forms of lymphoma get treated right away. But people with lymphoma that is growing slowly and not causing symptoms often do not need treatment at first.",
"     </p>",
"     <p>",
"      People with lymphoma often have one or more of the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Bone marrow transplant",
"        </strong>",
"        &ndash; This treatment replaces cells in the bone marrow that are killed by chemotherapy or radiation.",
"        <strong>",
"        </strong>",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H541280807\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the lymphoma comes back. Regular follow up will include talking with your doctor and having exams. Sometimes, your doctor will also do blood tests and imaging tests. Plus, you should watch for the symptoms listed above, because having those symptoms could mean the cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H541280814\">",
"      <span class=\"h1\">",
"       What happens if the lymphoma comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the lymphoma comes back, you might have more chemotherapy, radiation, or a bone marrow transplant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H541280821\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for lymphoma involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H541280828\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/50/31523?source=see_link\">",
"       Patient information: Hodgkin lymphoma in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/60/27588?source=see_link\">",
"       Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/37/13908?source=see_link\">",
"       Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/9/8339?source=see_link\">",
"       Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/28/40386?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15492 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40386=[""].join("\n");
var outline_f39_28_40386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280772\">",
"      What is lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280779\">",
"      What are the symptoms of lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280786\">",
"      Is there a test for lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280793\">",
"      What is lymphoma staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280800\">",
"      How is lymphoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280807\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280814\">",
"      What happens if the lymphoma comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280821\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541280828\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/6/25702\">",
"      Lymphatic system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/60/27588?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/9/8339?source=related_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/50/31523?source=related_link\">",
"      Patient information: Hodgkin lymphoma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_28_40387="Parathyroid cysts";
var content_f39_28_40387=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parathyroid cysts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40387/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40387/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40387/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40387/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40387/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40387/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/28/40387/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism is usually caused by a parathyroid adenoma, occasionally by primary parathyroid hyperplasia, and rarely by a parathyroid cyst or parathyroid carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30361?source=see_link\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parathyroid cysts are rare lesions of the neck or mediastinum, first described in 1880 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Microcysts of the parathyroid gland are primarily found in aging glands, often incidentally noted on autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/2\">",
"     2",
"    </a>",
"    ]. Generally, they have little clinical significance. Macrocysts of the parathyroid gland are larger than 1 cm, and these require clinical investigation.",
"   </p>",
"   <p>",
"    This topic will provide an overview of parathyroid cysts. Other aspects of primary hyperparathyroidism are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=see_link\">",
"     \"Parathyroid carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/0/35850?source=see_link\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid cysts can be divided in five categories based upon the presumed mechanism of cyst formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Developmental, arising from vestigial remnants of the third and fourth branchial clefts",
"     </li>",
"     <li>",
"      Coalescence of microcysts into macrocysts",
"     </li>",
"     <li>",
"      Degeneration of an adenoma, or rarely carcinoma, into a pseudocyst",
"     </li>",
"     <li>",
"      Accumulation of fluid in the parathyroid gland, forming a retention cyst",
"     </li>",
"     <li>",
"      Arising from vestigial remnants of Kursteiner canals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A parathyroid cyst may present as an asymptomatic neck mass or may be discovered as an incidental finding during neck surgery or imaging procedures performed for unrelated reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1\">",
"     1",
"    </a>",
"    ]. In over 85 percent of cases they are located in the neck, usually involving the lower parathyroid glands, whereas the rest can occur between the mandible and mediastinum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/7\">",
"     7",
"    </a>",
"    ]. Although these cysts vary in size, on average measuring 3 to 5 cm, masses as large as 10 to 12 cm have been reported, causing dyspnea, dysphagia, hoarseness, or rarely, innominate vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In a review of 93 patients with mediastinal parathyroid cysts, 9.5 percent had evidence of recurrent nerve injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parathyroid cysts are usually nonfunctional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/8\">",
"     8",
"    </a>",
"    ]. Nonfunctional cysts are more common in women, and present as a neck mass or are encountered at the time of a neck operation for some other reason. A review of 22,009 thyroidectomies and 2505 parathyroidectomies performed in a single institution over 25 years revealed the presence of 38 non-functional parathyroid cysts in 37 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1\">",
"     1",
"    </a>",
"    ]. Serum calcium, phosphorus and PTH levels were measured in 34 of 37 and were normal in all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1\">",
"     1",
"    </a>",
"    ]. In another review of 1769 case records of parathyroid surgeries, there were 48 cystic parathyroid lesions, of which 41 were functional parathyroid lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/9\">",
"     9",
"    </a>",
"    ]. The large predominance of functional parathyroid cysts in the latter study probably reflects referral bias of patients with primary hyperparathyroidism to an endocrine surgical referral center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional cysts occur more often in men and are more likely to be secondary to degenerative changes in a parathyroid tumor. Although the majority of functional parathyroid cysts cause mild hypercalcemia, patients may present with symptoms of acute parathyroid crisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ], as illustrated by the following cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 11 of 325 patients who underwent parathyroid surgery had parathyroid cysts. Two of the 11 patients had very high serum concentrations of calcium (17.1 and 14.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.3 and 3.5",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      respectively) and PTH, as well as nausea and altered consciousness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/8\">",
"       8",
"      </a>",
"      ]. In both patients, large areas within the cyst showed acute and chronic organization consistent with cystic degeneration of a parathyroid adenoma.",
"     </li>",
"     <li>",
"      Severe hypercalcemia (16 to 18",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4 to 4.5",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and very high PTH concentrations (333 to 1472",
"      <span class=\"nowrap\">",
"       pg/ml),",
"      </span>",
"      a profile typical of parathyroid carcinoma, have been reported in three other cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. In such cases, a giant tumor of the mandible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/12\">",
"       12",
"      </a>",
"      ] and an expansile rib lesion were described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/6\">",
"       6",
"      </a>",
"      ], presumably developing in response to markedly elevated PTH values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion on acute parathyroid crisis is located elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Parathyroid crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of parathyroid cysts includes thyroglossal duct cyst, branchial cleft cyst, cystic thyroid lesions, and parathyroid carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/2\">",
"     2",
"    </a>",
"    ]. Thyroglossal duct cysts are usually in the midline and move with deglutination in contrast to parathyroid cysts.",
"   </p>",
"   <p>",
"    Imaging modalities such as CT and ultrasound cannot differentiate thyroid from parathyroid cysts, and many parathyroid cysts can be intrathyroidal and may present as cold thyroid nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Although sestamibi scan can be positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/11\">",
"     11",
"    </a>",
"    ], it is not reliable and was negative in two of two cases of functioning parathyroid cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspiration of the cyst fluid accurately establishes the diagnosis of parathyroid cyst. A parathyroid cyst should be suspected in a patient who has a cystic mass that usually yields water-clear fluid on aspiration. The diagnosis can be confirmed by assay of the fluid for PTH. Nonfunctioning parathyroid cysts have cystic fluid PTH concentrations ranging from several hundred to over 400,000",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    with normal serum PTH concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. Conversely, in functioning parathyroid cysts, cystic fluid PTH levels can reach several million",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/15\">",
"     15",
"    </a>",
"    ]. These PTH levels were reported using midmolecule or C-terminal assays. The mechanism by which cystic PTH levels reach the peripheral circulation is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid cysts are histopathologically characterized by a smooth inner surface wall with a membranous lining, a solitary layer of cuboidal epithelium and parathyroid tissue within the cyst wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. They are rarely malignant. However, atypical cystic parathyroid adenoma is a very unusual clinical entity that may exhibit some pathologic features of carcinoma, but angio-invasion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastases are not present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/11\">",
"     11",
"    </a>",
"    ]. No specific molecular changes have been reported in parathyroid cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of symptomatic or functioning parathyroid cysts is surgical resection. Resection can be achieved through a cervical approach in all cysts located in the neck and in over two-thirds of mediastinal cysts. Thoracotomy or median sternotomy may be required for some mediastinal cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with functioning large cysts may be more likely to develop post-operative symptomatic hypocalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspiration of cyst fluid may be curative in some patients. In one case series, curative percutaneous aspiration of cyst fluid was achieved in 10 of 14 patients with nonfunctioning parathyroid cysts, nine with a single aspiration and one requiring a second aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1\">",
"     1",
"    </a>",
"    ]. Four of the 14 underwent surgical resection for recurrence of the cyst 6 to 48 months after the initial aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sclerotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and alcohol can be effective in recurrent lesions, but could result in fibrosis and recurrent laryngeal nerve palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40387/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hyperparathyroidism is usually caused by a parathyroid adenoma, occasionally by primary parathyroid hyperplasia, but only rarely (&lt;1 percent) by a parathyroid carcinoma or parathyroid cyst. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parathyroid cysts are most often located in the neck but can also occur in the mediastinum. Most are nonfunctional and present as a neck mass or are encountered at the time of a neck operation for some other reason. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspiration of the cyst fluid and confirmation of elevated PTH concentrations in the cyst fluid is diagnostic. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional cysts are more likely to be secondary to degenerative changes in a parathyroid tumor. The optimal treatment of functioning parathyroid cysts is surgical resection. Aspiration of cyst fluid may be curative in some patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/1\">",
"      Ippolito G, Palazzo FF, Sebag F, et al. A single-institution 25-year review of true parathyroid cysts. Langenbecks Arch Surg 2006; 391:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/2\">",
"      Fortson JK, Patel VG, Henderson VJ. Parathyroid cysts: a case report and review of the literature. Laryngoscope 2001; 111:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/3\">",
"      Ferrara BE, Hazell S, Parker TH, Rutland ED. Parathyroid cyst. South Med J 1985; 78:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/4\">",
"      Page GV, Burke ML, Metzger WT. Parathyroid cysts. Am Surg 1984; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/5\">",
"      Linos DA, Schoretsanitis G, Carvounis E. Parathyroid cysts of the neck and mediastinum. Case report. Acta Chir Scand 1989; 155:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/6\">",
"      Shields TW, Immerman SC. Mediastinal parathyroid cysts revisited. Ann Thorac Surg 1999; 67:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/7\">",
"      Ihm PS, Dray T, Sofferman RA, et al. Parathyroid cysts: diagnosis and management. Laryngoscope 2001; 111:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/8\">",
"      Calandra DB, Shah KH, Prinz RA, et al. Parathyroid cysts: a report of eleven cases including two associated with hyperparathyroid crisis. Surgery 1983; 94:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/9\">",
"      McCoy KL, Yim JH, Zuckerbraun BS, et al. Cystic parathyroid lesions: functional and nonfunctional parathyroid cysts. Arch Surg 2009; 144:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/10\">",
"      Gurbuz AT, Peetz ME. Giant mediastinal parathyroid cyst: an unusual cause of hypercalcemic crisis--case report and review of the literature. Surgery 1996; 120:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/11\">",
"      Wani S, Hao Z. Atypical cystic adenoma of the parathyroid gland: case report and review of literature. Endocr Pract 2005; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/12\">",
"      Oh A, Mojica P, Sullivan M, et al. Malignant hypercalcemia associated with a parathyroid macrocyst and the early genesis of a giant cell tumor. Am J Otolaryngol 2006; 27:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/13\">",
"      Ujiki MB, Nayar R, Sturgeon C, Angelos P. Parathyroid cyst: often mistaken for a thyroid cyst. World J Surg 2007; 31:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/14\">",
"      Pacini F, Antonelli A, Lari R, et al. Unsuspected parathyroid cysts diagnosed by measurement of thyroglobulin and parathyroid hormone concentrations in fluid aspirates. Ann Intern Med 1985; 102:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40387/abstract/15\">",
"      Spitz AF. Management of a functioning mediastinal parathyroid cyst. J Clin Endocrinol Metab 1995; 80:2866.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2027 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40387=[""].join("\n");
var outline_f39_28_40387=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30361?source=related_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_28_40388="Pancreas anatomy PI";
var content_f39_28_40388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Pancreas anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 571px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pancreas is an organ that is found behind the stomach. It makes hormones and juices that help the body break down food.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40388=[""].join("\n");
var outline_f39_28_40388=null;
var title_f39_28_40389="Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women";
var content_f39_28_40389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40389/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40389/contributors\">",
"     Eman Elkadry, MD, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40389/contributors\">",
"     Leah K Moynihan, RNC, MSN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40389/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40389/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40389/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40389/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/28/40389/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myofascial pelvic pain syndrome (MPPS) describes a disorder in which pelvic pain is attributed to short, tight, tender pelvic floor muscles, usually with hypersensitive trigger points. The pain may occur in the pelvis, vagina, vulva, rectum, or bladder, or in more distant referral areas such as the thighs, buttocks, or lower abdomen. Commonly associated symptoms include a sense of aching, heaviness, or burning in these areas, sometimes with symptoms of overactive bladder, constipation, or dyspareunia. Many experts believe that many, if not most, women with chronic pelvic pain have some degree of MPPS.",
"   </p>",
"   <p>",
"    Clinical manifestations and diagnosis of myofascial pain syndrome in women are reviewed here. Treatment of this condition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5305?source=see_link\">",
"     \"Treatment of myofascial pelvic pain syndrome in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of myofascial pelvic pain is unclear in most cases. A variety of etiologies are possible, including pelvic organ pathology, neuromuscular disorders, and psychologic causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/1\">",
"     1",
"    </a>",
"    ]. This problem is made more complicated because deep muscular pain and visceral pain can be difficult, if not impossible, for most patients to differentiate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trigger points are the hallmark of myofascial pain. Trigger points have several features in common, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One or more trigger points may be present",
"     </li>",
"     <li>",
"      They are located within a tight band of muscle",
"     </li>",
"     <li>",
"      They cause local pain that is also referred to distant areas",
"     </li>",
"     <li>",
"      Pain or tenderness may occur in the absence of stimulation or only when pressure is applied",
"     </li>",
"     <li>",
"      A local twitch response occurs when firm pressure is applied (strummed) across the point. However, this is not always palpable, especially in the pelvic floor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over time, muscles with trigger points become weak, tender, and shortened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/5\">",
"     5",
"    </a>",
"    ]. This, in turn, can cause surrounding muscle groups to also contract and develop trigger points, thereby worsening myofascial pain and related symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pelvic floor is believed to be at risk of developing myofascial trigger points because pelvic floor muscles (1) are involved in several different kinds of activities, including musculoskeletal support of the upper body and lower extremities, and control of bladder, bowel, and sexual function, (2) must elongate and contract eccentrically, and (3) are affected by physiologic and psychologic stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myofascial trigger points are thought to develop when acute trauma or the repetitive microtraumas that occur with daily activity and exercise cause high intensity stimulation of the motor end plate of the pelvic floor muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, anxiety may predispose some women to continuously contract their muscles, including those of the pelvic floor. Short-term or chronic pelvic pain can similarly cause a woman to unconsciously contract her pelvic floor muscles. Poor posture and joint malalignment (eg, internal rotation of the hips), leg length discrepancy, and dysfunction of the sacroiliac joint, are orthopedic abnormalities that increase the strain on the pelvic floor. Additional potential causes of pelvic myofascial trigger points are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef69783 \" href=\"mobipreview.htm?8/14/8427\">",
"     table 1",
"    </a>",
"    ). The bladder is often affected by these trigger points because of the proximity in the spinal cord between the afferent nerve endings of deep muscles of the pelvic floor and the parasympathetic nerves of the bladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged muscle contraction, spasm, and inappropriately high muscle tone are thought to diminish blood supply and increase oxygen demand of the muscles of the pelvic floor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Ischemic muscle may secrete vasoactive and neuroactive substances, which further sensitize muscle nociceptors, alter receptor field properties, and convert wide-band mechanoreceptors to nociceptors, resulting in pain and perpetuating this cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/11\">",
"     11",
"    </a>",
"    ]. Fibrosis may eventually occur.",
"   </p>",
"   <p>",
"    Changes in the central processing of painful stimuli may also play a role. Such changes may lower the pain threshold, allow nonpainful stimuli to cause pain (allodynia), and increase the field, degree, or duration of pain (hyperalgesia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with MPPS have pelvic floor trigger points that are exquisitely tender. In one series, almost all of the patients had trigger points in the levator ani muscles (92 percent), and other muscle groups were commonly affected: suprapubic (65 percent), iliopsoas (43 percent), obturator internus (45 percent), and piriformis (8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/12\">",
"     12",
"    </a>",
"    ]. The variation in trigger point location may account for the various presenting symptoms and clinical picture.",
"   </p>",
"   <p>",
"    Trigger points in the pelvic floor often refer pain to the vagina, vulva, perineum, rectum, and bladder, but pain can be referred to more distant areas such as the thighs, buttocks, or lower abdomen. Irritative symptoms may be more prominent than pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Symptoms of MPPS include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Pelvic/abdominal",
"      </span>",
"      pain (often with severe dysmenorrhea)",
"     </li>",
"     <li>",
"      Urinary tract symptoms (eg, frequency, urgency, incontinence, nocturia, dysuria, sensation of incomplete emptying, bladder pain)",
"     </li>",
"     <li>",
"      Vulvovaginal discomfort",
"     </li>",
"     <li>",
"      Dyspareunia",
"     </li>",
"     <li>",
"      Rectal fullness or constipation, dyschezia",
"     </li>",
"     <li>",
"      Rectal, vaginal, or bladder spasms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myofascial pelvic pain can be either continuous or episodic and may manifest as a sense of aching, heaviness, pressure, or burning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/3\">",
"     3",
"    </a>",
"    ]; occasionally, women report cramping or a sense of spasm. It is not associated with the menstrual cycle, although, in some women, the pain is exacerbated by menses. The pain often mimics that of visceral pain (ie, poorly localized and often referred to a distant cutaneous site, which may be tender). Alternatively, the woman may note deep visceral discomfort when wearing certain types of fabrics or when she is in certain positions (eg, prolonged sitting) that compress the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/2\">",
"     2",
"    </a>",
"    ]. Sometimes sexual intercourse or certain activities can trigger a flare. Women may report a feeling of having a urinary tract infection or vaginitis after these triggers, but cultures are consistently negative.",
"   </p>",
"   <p>",
"    Myofascial pelvic pain that begins as a local process can become widespread or more severe, sometimes as a result of diagnostic interventions or surgical attempts to resolve pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. There seems to be little correlation between any single presenting symptom and physical finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Relation to other pelvic pain syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a correlation between visceral inflammation and myofascial abnormalities in tissues that share the same innervation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/12\">",
"     12",
"    </a>",
"    ]. Perhaps for this reason, there is significant overlap between the pain of MPPS and the pain of painful bladder",
"    <span class=\"nowrap\">",
"     syndrome/interstitial",
"    </span>",
"    cystitis",
"    <span class=\"nowrap\">",
"     (PBS/IC)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/5,15,16\">",
"     5,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8330?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We have noted that women with a diagnosis of",
"    <span class=\"nowrap\">",
"     PBS/IC,",
"    </span>",
"    vulvodynia, or recurrent urinary tract infection or vaginitis, often have multiple trigger points on examination of their pelvic floor. Other abnormalities of the pelvic girdle (hips, lower abdomen, low back, thighs) also frequently occur. In the group of patients mentioned above, 31 percent had a diagnosis of",
"    <span class=\"nowrap\">",
"     PBS/IC,",
"    </span>",
"    10 percent had endometriosis, and 26 percent had \"recurrent urinary tract infections.\" In addition, 26 percent had previously undergone laparoscopy, 16 percent had prior hysterectomy, 12 percent had prior hydrodistention, and 6 percent had prior urethral dilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MPPS is clinical, based upon characteristic findings on the history and physical examination (see below).",
"   </p>",
"   <p>",
"    The general approach to evaluation of women with chronic pelvic pain is described in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31864?source=see_link\">",
"     \"Evaluation of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When taking the history, ask about the effect of positioning (sitting, standing for long periods), intercourse, daily activities, stress, and whether the patient has had urinary tract or vaginal yeast infections that were not culture-proven.",
"   </p>",
"   <p>",
"    Physical examination should include palpation of the connective tissues and muscles of the abdomen, hips and pelvis. The internal pelvic examination should include an assessment of the vaginal mucosa and pelvic floor musculature.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the connective tissues by rolling the skin lightly between two fingers (not pinching); tender areas often feel thickened or tight and will elicit sharp pain or a deep \"bruise-like\" pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with MPPS often have diffuse tenderness in the abdomen, particularly over the rectus abdominis and external oblique muscle groups. Examine the diastasis recti for hernia. This assessment is described separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link\">",
"       \"Overview of abdominal hernias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Apply pressure over the suprapubic area to see if pain is elicited, especially as the bladder is compressed.",
"     </li>",
"     <li>",
"      Manipulate any surgical scars. Scars should move easily and without restrictions; scars that are puckered, have limited movement, or are tender could be a source of MPPS or exacerbate symptoms.",
"     </li>",
"     <li>",
"      Observe the external genitalia as the woman bears down and also as she contracts the pelvic floor. If the woman has difficulty contracting, ask her to squeeze the vaginal muscles around a single digit or try to \"pick up a dime\" with the vaginal muscles. Observe as the pelvic floor contracts and relaxes; pelvic floor muscles with trigger points are often weak, have limited mobility, move paradoxically and slowly or incompletely relax.",
"     </li>",
"     <li>",
"      Provoke an anal wink reflex by gently stroking the skin immediately surrounding the anus; this results in a reflexive contraction of the external anal sphincter. The reflex may be absent because the pelvic floor muscles are already contracted. However, the absence of this reflex could also be due to nerve damage and interruption of the spinal arc.",
"     </li>",
"     <li>",
"      Perform a speculum examination, with attention to the condition of the vaginal mucosa. Are there signs of a hypoestrogenic state or infection? Both hypoestrogenism and vaginal infections can trigger or exacerbate MPPS.",
"     </li>",
"     <li>",
"      To assess the pelvic floor, insert one or two fingers into the vagina. Perform bimanual examination of the uterus, bladder, and adnexae. Proceed slowly and gently and ask the woman to indicate if she has discomfort at any point. Ask her to rate her pain on a scale of zero (feels pressure, but no pain) to 10 (worst pain imaginable).",
"     </li>",
"     <li>",
"      Often before starting to examine the pelvic floor muscles, we apply pressure to the thigh as a baseline reference of how much discomfort would be normally expected. We then apply posterior pressure (enough to blanch the examiner's fingernail) to the obturator internus, located laterally and deep to the vaginal opening. Asking the patient to abduct the knee against resistance while the hip is flexed will make this area easier to palpate. Sweep the fingers medially to locate the iliococcygeus, noting any areas of tenderness, tension, or banding. Trigger points can often be localized in areas of tight or bandy muscles, which may feel like violin strings; these areas can be exquisitely tender with even light palpation. Pain is usually associated with involuntary spasm of the pelvic floor muscles (eg, bulbospongiosus, ischiocavernosus, transversus perineum, sphincter ani, piriformis, levator ani, obturator internus in any combination) (",
"      <a class=\"graphic graphic_figure graphicRef67298 \" href=\"mobipreview.htm?18/0/18435\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/5\">",
"       5",
"      </a>",
"      ]. In particular, the levator ani muscle group can develop hypertonus, myalgia, overuse, and fatigue. If there is severe pain elicited on palpation of one muscle group, we do not proceed to check all muscle groups on the same side. Instead, we examine the same muscle group on the other side of the pelvis, to assess symmetry of pain. Whether trigger points can be imaged successfully is an area of investigation. We have not observed any direct correlation between which muscle groups are affected and the symptom complex that women exhibit.",
"     </li>",
"     <li>",
"      Assess the urethral sphincter and pubococcygeus in the vagina by gently compressing these areas between your finger and the pubic symphysis. If this area is involved, the patient will often note a feeling of urinary urgency or tenderness (",
"      <a class=\"graphic graphic_figure graphicRef82007 \" href=\"mobipreview.htm?25/8/25736\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Perform a rectal or vaginal examination to assess the puborectalis. A rectal examination is necessary to assess the anal sphincter and coccyx.",
"     </li>",
"     <li>",
"      If the patient is referred to a physical therapist, the therapist should assess all muscle groups with a thorough assessment of posture, gait, range of motion of the trunk and hips, pelvic instability, and lower extremity strength, mobility, and length [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33127?source=see_link\">",
"       \"Pelvic floor physical therapy for management of myofascial pelvic pain syndrome in women\"",
"      </a>",
"      .) Factors such as scoliosis or other spinal abnormalities often contribute to the pain and usually require a longer course of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccygodynia, pelvic floor tension myalgia, piriformis syndrome, levator ani spasm syndrome, and proctalgia fugax share hypertonicity of some of the pelvic musculature as an underlying problem, and may represent various manifestations of the same disease state. Other muscle groups can also refer pain to the pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40389/abstract/5\">",
"     5",
"    </a>",
"    ]. Of course, underlying pathology of the bladder, pelvic organs and bowels must be excluded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trigger points in the piriformis muscle can cause pain in the low back, hips, groin, buttocks, perineum, and posterior thigh, which can in turn cause dyspareunia and pain with defecation.",
"     </li>",
"     <li>",
"      Pain in the quadratus lumborum is often felt along the iliac crest, the left and right lower quadrant of the abdomen, the upper outer groin to the upper outer thigh, the sacroiliac joint, or in the low buttock.",
"     </li>",
"     <li>",
"      Trigger points in the rectus abdominis muscles may cause pain or burning in the abdomen or a sense of bloating or fullness. Abdominal myofascial pain is easily confused with pain of a visceral origin. The pain's origins can usually be determined by having the patient Valsalva (by performing a half sit-up from the supine position), which tightens the muscles; if pain is noted with palpation during Valsalva, it is likely muscular. There is some evidence that visceral pain can cause myofascial pain and trigger points and vice versa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myofascial pelvic pain syndrome (MPPS) describes a disorder in which pelvic pain is attributed to short, tight, tender pelvic floor muscles, usually with hypersensitive trigger points. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Trigger points of the pelvic floor often refer pain to the vagina, vulva, perineum, rectum, and bladder, but pain can be referred to more distant areas such as the thighs, buttocks, or lower abdomen. Irritative symptoms (eg, urinary urgency, vulvovaginal burning, rectal fullness) may be more prominent than pain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of MPPS is clinical, based on characteristic findings on history and physical examination. Physical examination should include palpation of the connective tissues and muscles of the abdomen and pelvis. The internal pelvic examination should include an assessment of the vaginal mucosa and pelvic floor musculature. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/1\">",
"      Srinivasan AK, Kaye JD, Moldwin R. Myofascial dysfunction associated with chronic pelvic floor pain: management strategies. Curr Pain Headache Rep 2007; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/2\">",
"      Prendergast SA, Weiss JM. Screening for musculoskeletal causes of pelvic pain. Clin Obstet Gynecol 2003; 46:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/3\">",
"      Alvarez DJ, Rockwell PG. Trigger points: diagnosis and management. Am Fam Physician 2002; 65:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/4\">",
"      Cummings M, Baldry P. Regional myofascial pain: diagnosis and management. Best Pract Res Clin Rheumatol 2007; 21:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/5\">",
"      Doggweiler-Wiygul R, Wiygul JP. Interstitial cystitis, pelvic pain, and the relationship to myofascial pain and dysfunction: a report on four patients. World J Urol 2002; 20:310.",
"     </a>",
"    </li>",
"    <li>",
"     Weiss, JM. Chronic pelvic pain and myofascial trigger points. Surgical Physician Assistant 2000;.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/7\">",
"      Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol 2001; 166:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/8\">",
"      Rosenbaum TY, Owens A. The role of pelvic floor physical therapy in the treatment of pelvic and genital pain-related sexual dysfunction (CME). J Sex Med 2008; 5:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/9\">",
"      Issberner U, Reeh PW, Steen KH. Pain due to tissue acidosis: a mechanism for inflammatory and ischemic myalgia? Neurosci Lett 1996; 208:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/10\">",
"      Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil 1998; 79:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/11\">",
"      Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain 2001; 17:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/12\">",
"      FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. I: Background and patient evaluation. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/13\">",
"      Ingber MS, Peters KM, Killinger KA, et al. Dilemmas in diagnosing pelvic pain: multiple pelvic surgeries common in women with interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/14\">",
"      FitzGerald MP, Brensinger C, Brubaker L, et al. What is the pain of interstitial cystitis like? Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/15\">",
"      Peters KM, Carrico DJ, Kalinowski SE, et al. Prevalence of pelvic floor dysfunction in patients with interstitial cystitis. Urology 2007; 70:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40389/abstract/16\">",
"      Bassaly R, Tidwell N, Bertolino S, et al. Myofascial pain and pelvic floor dysfunction in patients with interstitial cystitis. Int Urogynecol J 2011; 22:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5480 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40389=[""].join("\n");
var outline_f39_28_40389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Relation to other pelvic pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5480\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5480|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/0/18435\" title=\"figure 1\">",
"      Perineal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/8/25736\" title=\"figure 2\">",
"      Pelvic floor muscles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5480|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/14/8427\" title=\"table 1\">",
"      Etiology of pelvic trigger points",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31864?source=related_link\">",
"      Evaluation of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8330?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33127?source=related_link\">",
"      Pelvic floor physical therapy for management of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5305?source=related_link\">",
"      Treatment of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_28_40390="Cyclosporine (systemic): Patient drug information";
var content_f39_28_40390=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyclosporine (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/8/30858?source=see_link\">",
"     see \"Cyclosporine (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/55/36729?source=see_link\">",
"     see \"Cyclosporine (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gengraf&reg;;",
"     </li>",
"     <li>",
"      Neoral&reg;;",
"     </li>",
"     <li>",
"      SandIMMUNE&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8012540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cyclosporine&reg;;",
"     </li>",
"     <li>",
"      Neoral&reg;;",
"     </li>",
"     <li>",
"      Rhoxal-cyclosporine;",
"     </li>",
"     <li>",
"      Sandimmune&reg; I.V.;",
"     </li>",
"     <li>",
"      Sandoz-Cyclosporine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will have more chance of getting infections. Avoid crowds and people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is more than 1 brand of this drug. One brand cannot safely be used for the other. Your doctor will tell you about any needed change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting lymphoma or other cancers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700695",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney problems in some patients. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for psoriasis AND you got other drugs to treat this health problem, your chance of skin cancer may be higher.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep the body from harming the organ after an organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat autoimmune diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat very bad psoriasis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cyclosporine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703458",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Cancer, psoriasis and taking light therapy, poor kidney function, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are getting radiation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair growth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix Neoral&reg; solution in glass with orange or apple juice at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695436",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix Sandimmune&reg; solution in glass with 1 cup of milk, chocolate milk, or orange juice at room temperature and drink it  right away. Rinse glass with more juice or milk and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in the original container at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of the solution not used after 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neoral&reg; solutions may gel at temperatures less than 68&deg;F (20&deg;C). Bring to room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11645 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40390=[""].join("\n");
var outline_f39_28_40390=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012539\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012540\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030345\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030347\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030346\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030351\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030352\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030354\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030349\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030350\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030355\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030356\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/26/14756?source=related_link\">",
"      Cyclosporine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/52/6980?source=related_link\">",
"      Cyclosporine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/42/23202?source=related_link\">",
"      Cyclosporine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/8/30858?source=related_link\">",
"      Cyclosporine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/55/36729?source=related_link\">",
"      Cyclosporine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_28_40391="Glipizide: Drug information";
var content_f39_28_40391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glipizide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/19/16693?source=see_link\">",
"    see \"Glipizide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/39/10870?source=see_link\">",
"    see \"Glipizide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Glucotrol XL&reg;;",
"     </li>",
"     <li>",
"      Glucotrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     Initial: 5 mg once daily; titrate in 2.5-5 mg increments no more frequently than every few days based on blood glucose response; if once-daily dose is ineffective, may divide the dose; doses &gt;15 mg/day should be administered in divided doses. Maximum recommended once-daily dose: 15 mg; maximum recommended total daily dose: 40 mg (some clinicians recommend a maximum total daily dose of 20 mg [Defronzo, 1999]).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release tablet (Glucotrol XL&reg;):",
"     </i>",
"     Initial: 5 mg once daily; usual dose: 5-10 mg once daily; maximum recommended dose: 20 mg/day; dosage adjustments based on blood glucose monitoring should be made no more frequently than every 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      When transferring from immediate release to extended release glipizide:",
"     </b>",
"     May switch the total daily dose of immediate release to the nearest equivalent daily dose of the extended release tablet and administer once daily; alternatively, may initiate extended release at 5 mg once daily and titrate accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      When transferring from insulin to glipizide immediate release or extended release tablet:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Current insulin requirement &le;20 units:",
"     </i>",
"     Discontinue insulin and initiate glipizide at usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Current insulin requirement &gt;20 units:",
"     </i>",
"     Decrease insulin by 50% and initiate glipizide at usual dose; gradually decrease insulin dose based on patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conversion from therapy with long half-life agents:",
"     </b>",
"     Observe patient carefully for 1-2 weeks when converting from a longer half-life agent (eg, chlorpropamide) to glipizide due to overlapping hypoglycemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     Initial: 2.5 mg once daily; consider titrating by 2.5-5 mg/day at 1- to 2-week intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release tablet:",
"     </i>",
"     Initial and maintenance dosing should be on the lower end of the recommended range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F176332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling although caution is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The following guidelines have been used by some clinicians (Aronoff, 2007): GFR &le;50 mL/minute: Decrease dose by 50%.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F176333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     Initial: 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Extended release tablet:",
"     </i>",
"     There are no dosage adjustments provided in manufacturer's labeling; however, drug undergoes hepatic metabolism and use of a lower initial and maintenance dose should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucotrol&reg;: 5 mg, 10 mg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucotrol XL&reg;: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer immediate release tablets 30 minutes before a meal (preferably before breakfast if once-daily dosing) to achieve greatest reduction in postprandial hyperglycemia. Extended release tablets should be given with breakfast. Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise to lower blood glucose; may be used in combination with metformin or insulin in patients whose hyperglycemia cannot be controlled by diet and exercise in conjunction with a single oral hypoglycemic agent",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F176378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GlipiZIDE may be confused with glimepiride, glyBURIDE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Glucotrol&reg; may be confused with Glucophage&reg;, Glucotrol&reg; XL, glyBURIDE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Syncope (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 7%), nervousness (4%), anxiety (&lt;3%), depression (&lt;3%), hypoesthesia (&lt;3%), insomnia (&lt;3%), pain (&lt;3%), drowsiness (2%), headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus (1% to &lt;3%), eczema (1%), erythema (1%), maculopapular eruptions (1%), morbilliform eruptions (1%), rash (1%), urticaria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1% to 5%), flatulence (3%), constipation (1% to &lt;3%), nausea (1% to &lt;3%), dyspepsia (&lt;3%), vomiting (&lt;3%), abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (4%), arthralgia (&lt;3%), leg cramps (&lt;3%), myalgia (&lt;3%), paresthesia (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Blood urea nitrogen increased, creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinitis (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, anorexia, aplastic anemia, arrhythmia, blood in stool, cholestatic jaundice, conjunctivitis, disulfiram-like reaction, edema, gait instability, hemolytic anemia, hypertension, hypertonia, hyponatremia, jaundice, leukopenia, liver injury, migraine, pancytopenia, photosensitivity, porphyria, retinal hemorrhage, SIADH, thrombocytopenia, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glipizide or any component of the formulation; type 1 diabetes mellitus (insulin dependent, IDDM); diabetic ketoacidosis (with or without coma)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function; use with caution. Autonomic neuropathy, advanced age, and concomitant use of beta-blockers or other sympatholytic agents may impair the patient&rsquo;s ability to recognize the signs and symptoms of hypoglycemia; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI tract stricture/narrowing: The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction. Avoid use of extended release tablets (Glucotrol XL&reg;) in patients with severe gastrointestinal narrowing or esophageal dysmotility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F176365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of GlipiZIDE. Management: Administer glipizide at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the hypoglycemic effect of GlipiZIDE. Posaconazole may increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F176322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Caution with ethanol (may cause hypoglycemia or rare disulfiram reaction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: A delayed release of insulin may occur if glipizide is taken with food. Immediate release tablets should be administered 30 minutes before meals to avoid erratic absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Herbs with hypoglycemic properties may enhance the hypoglycemic effect of glipizide. This includes alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies; therefore, glipizide is classified as pregnancy category C. Glipizide crosses the placenta. Severe hypoglycemia lasting 4-10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. The manufacturer recommends if glipizide is used during pregnancy it should be discontinued at least 1 month before the expected delivery date. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F176312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data from initial studies note that glipizide was not detected in breast milk. Breast-feeding is not recommended by the manufacturer. Potentially, hypoglycemia may occur in a nursing infant exposed to a sulfonylurea via breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F176313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take immediate release tablets 30 minutes before meals (preferably before breakfast if once-daily dosing); extended release tablets should be taken with breakfast. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F176310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (GlipiZIDE ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $12.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $40.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $69.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (GlipiZIDE XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $12.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $40.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $80.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Glucotrol XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $26.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $87.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $170.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (GlipiZIDE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $36.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $63.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Glucotrol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $89.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $164.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypoglycemia (fatigue, excessive hunger, profuse sweating, numbness of extremities), blood glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     every 3 months for unstable patients and twice yearly for stable patients",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F176301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F176314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiab (HR, PL);",
"     </li>",
"     <li>",
"      Apamid (SE);",
"     </li>",
"     <li>",
"      Brilizid (PH);",
"     </li>",
"     <li>",
"      Diabes (TW);",
"     </li>",
"     <li>",
"      Diasef (HK, SG);",
"     </li>",
"     <li>",
"      Dibizide (MY);",
"     </li>",
"     <li>",
"      Digrin (KP);",
"     </li>",
"     <li>",
"      Dipazide (TH);",
"     </li>",
"     <li>",
"      Flumedil (MX);",
"     </li>",
"     <li>",
"      Gabaz (MX);",
"     </li>",
"     <li>",
"      Gipzide (TH);",
"     </li>",
"     <li>",
"      Glibenese (AE, AT, BE, BF, BH, BJ, CH, CI, CY, DE, DK, EG, ET, FI, FR, GH, GM, GN, GR, IL, IQ, IR, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PL, QA, RU, SA, SC, SD, SE, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Glibenese GITS (PL);",
"     </li>",
"     <li>",
"      Glibetin (TW);",
"     </li>",
"     <li>",
"      Glican (SV);",
"     </li>",
"     <li>",
"      Glidiab (TW);",
"     </li>",
"     <li>",
"      Glipid (NZ);",
"     </li>",
"     <li>",
"      Glipimed (TH);",
"     </li>",
"     <li>",
"      Glipizide (PL);",
"     </li>",
"     <li>",
"      Glipizide BP (PL);",
"     </li>",
"     <li>",
"      Glix (MY);",
"     </li>",
"     <li>",
"      Glizide (TH);",
"     </li>",
"     <li>",
"      Gluco-Rite (IL);",
"     </li>",
"     <li>",
"      Glucodiab (TH);",
"     </li>",
"     <li>",
"      Glucolip (IN);",
"     </li>",
"     <li>",
"      Gluconil (PH);",
"     </li>",
"     <li>",
"      Glucotrol XL (BB, BM, BS, BZ, CL, GY, HK, ID, JM, SR, TT);",
"     </li>",
"     <li>",
"      Glucozide (TW);",
"     </li>",
"     <li>",
"      Glupizide (TW);",
"     </li>",
"     <li>",
"      Glygen (TH);",
"     </li>",
"     <li>",
"      Glynase (IN, SG);",
"     </li>",
"     <li>",
"      Glyzip (IN);",
"     </li>",
"     <li>",
"      Luditec (MX);",
"     </li>",
"     <li>",
"      Melizid (FI);",
"     </li>",
"     <li>",
"      Melizide (AU, SG);",
"     </li>",
"     <li>",
"      Mindiab (DK, EE, FI, HK, NO, PK, RU, SE);",
"     </li>",
"     <li>",
"      Minidiab (AE, AT, AU, BE, BF, BG, BH, BJ, BR, CI, CN, CY, CZ, EG, ET, FR, GH, GM, GN, HK, HN, HU, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, PH, PL, PT, QA, SA, SC, SD, SL, SN, SY, TH, TN, TR, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Minodiab (AR, CR, ES, GB, GR, GT, IE, MX, NI, PA);",
"     </li>",
"     <li>",
"      Napizide (TW);",
"     </li>",
"     <li>",
"      Ozidia (FR);",
"     </li>",
"     <li>",
"      Pezide (TH);",
"     </li>",
"     <li>",
"      Singloben (MX);",
"     </li>",
"     <li>",
"      Sucrazide (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Sunglucon (HK);",
"     </li>",
"     <li>",
"      Topizide (TH);",
"     </li>",
"     <li>",
"      Xeltic (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release: Rapid and complete; delayed with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 10-11 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98% to 99%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 90% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C9; forms metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1-3 hours; extended release tablets: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;10% as unchanged drug; 80% as metabolites); feces (10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al, &ldquo;Intensive Blood Glucose Control and Vascular Outcomes in Patients With Type 2 Diabetes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(24):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/18539916/pubmed\" id=\"18539916\" target=\"_blank\">",
"        18539916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 112.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Study of the Effects of Hypoglycemia Agents on Vascular Complications in Patients With Adult-onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated With Tolbutamide. The University Group Diabetes Program,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1976, 25(12):1129-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/992232/pubmed\" id=\"992232\" target=\"_blank\">",
"        992232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berelowitz M, Fischette C, Cefalu W, et al, &ldquo;Comparative Efficacy of a Once-Daily Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Patients With NIDDM,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 1994, 17(12):1460-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/7882817/pubmed\" id=\"7882817\" target=\"_blank\">",
"        7882817",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brodows RG, &ldquo;Benefits and Risks With Glyburide and Glipizide in Elderly NIDDM Patients,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 1992, 15(1):75-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/1737544/pubmed\" id=\"1737544\" target=\"_blank\">",
"        1737544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1999, 131(4):281-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/10454950/pubmed\" id=\"10454950\" target=\"_blank\">",
"        10454950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):854-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/9742977/pubmed\" id=\"9742977\" target=\"_blank\">",
"        9742977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/9935017/pubmed\" id=\"9935017\" target=\"_blank\">",
"        9935017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goran B, Bo B, Martin F, et al, &ldquo;Glipizide-Induced Severe Hypoglycemia,&rdquo;",
"      <i>",
"       Acta Endocrinol (Copenh)",
"      </i>",
"      , 1981, 98(Suppl 245):13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klamann A, Sarfert P, Launhardt V, et al, &ldquo;Myocardial Infarction in Diabetic vs Nondiabetic Subjects. Survival and Infarct Size Following Therapy With Sulfonylureas (Glibenclamide),&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2000, 21(3):220-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/10639304/pubmed\" id=\"10639304\" target=\"_blank\">",
"        10639304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kradjan WA, Kobayashi KA, Bauer LA, et al, &ldquo;Glipizide Pharmacokinetics: Effects of Age, Diabetes, and Multiple Dosing,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1989, 29(12):1121-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/2693502/pubmed\" id=\"2693502\" target=\"_blank\">",
"        2693502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kradjan WA, Takeuchi KY, Opheim KE, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Glipizide After Once-Daily and Divided Doses,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(4):465-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/7479199/pubmed\" id=\"7479199\" target=\"_blank\">",
"        7479199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meinert CL, Knatterud GL, Prout TE, et al, &ldquo;A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset Diabetes. II. Mortality Results,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1970, 19:789-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/4926376/pubmed\" id=\"4926376\" target=\"_blank\">",
"        4926376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Keefe JH, Blackstone EH, Sergeant P, et al, &ldquo;The Optimal Mode of Coronary Revascularization for Diabetics. A Risk-Adjusted Long-Term Study Comparing Coronary Angioplasty and Coronary Bypass Surgery,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1998, 19(11):1696-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/9857923/pubmed\" id=\"9857923\" target=\"_blank\">",
"        9857923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenstock J, Corrao PJ, Goldberg RB, et al, &ldquo;Diabetes Control in the Elderly: A Randomized, Comparative Study of Glyburide Versus Glipizide in Noninsulin Dependent Diabetes Mellitus,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1993, 15(6):1031-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/8111800/pubmed\" id=\"8111800\" target=\"_blank\">",
"        8111800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study (UKPDS) Group, \"Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33),\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/28/40391/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8492 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-85249D4AE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40391=[""].join("\n");
var outline_f39_28_40391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176326\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176370\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176330\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176331\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176332\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176333\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176300\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176286\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176305\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176304\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176378\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176368\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176308\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176290\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176365\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176295\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176322\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176296\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176311\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176337\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176312\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176313\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176310\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176298\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176301\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176314\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176289\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176307\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8492|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/19/16693?source=related_link\">",
"      Glipizide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/39/10870?source=related_link\">",
"      Glipizide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_28_40392="Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients";
var content_f39_28_40392=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40392/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40392/contributors\">",
"     Judith S Currier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40392/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40392/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40392/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40392/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/28/40392/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10000541\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As patients are living longer with HIV, cardiovascular disease has emerged as an important cause of morbidity and mortality among infected patients. Even with effective antiretroviral therapy, HIV-infected patients have a higher risk of myocardial infarction and cardiovascular death than age-matched uninfected controls. Although an increased prevalence of traditional risk factors, such as dyslipidemia and smoking, among HIV-infected patients likely contributes to this increased cardiovascular morbidity, growing evidence suggests that HIV infection and treatment are more directly linked to atherogenesis, endothelial dysfunction, and coagulation abnormalities, likely through inflammation and immune dysregulation.",
"   </p>",
"   <p>",
"    Measures of subclinical cardiovascular disease and the pathogenesis of atherosclerosis in HIV-infected patients are discussed here. The epidemiology of cardiovascular morbidity and traditional risk factors and the management of dyslipidemia and cardiovascular risk in HIV-infected patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10000548\">",
"    <span class=\"h1\">",
"     SUBCLINICAL ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease has emerged as an important cause of death in HIV-infected patients, as illustrated by clinical studies evaluating such hard endpoints as stroke or myocardial infarctions (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    ). However, HIV patients are generally young and thus have overall low short-term cardiovascular risk and few events. Therefore, many clinical studies rely upon surrogate markers to indirectly assess the burden of cardiovascular disease. These studies have demonstrated an increased prevalence of subclinical atherosclerosis in HIV-infected patients. Such measurements include intima media thickening (IMT) and intraluminal arterial plaque as assessed by ultrasound and evaluation of coronary artery calcification and plaque by computed tomography. These measurements have been moderately associated with coronary atherosclerosis and the future risk of a cardiovascular event in studies of HIV-uninfected adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H10122160#H10122160\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Arterial intima-media thickness'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H1268874#H1268874\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Coronary artery calcification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most, but not all studies of IMT of the carotid artery and coronary arteries in asymptomatic adults have found an increase in measurement with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/2-11\">",
"     2-11",
"    </a>",
"    ]. In a meta-analysis of observational studies evaluating subclinical atherosclerosis in HIV-infected patients, the following observations were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 13 studies that compared carotid IMT in HIV-infected versus uninfected patients, all except for two reported a trend towards higher carotid IMT with HIV. However, the weighted mean difference between HIV-positive and negative patients was very small, 0.04 mm (95% CI 0.02-0.06). Moreover, there was significant statistical and clinical heterogeneity between the studies, including differences in measurement technique and underlying traditional cardiovascular risk factors.",
"     </li>",
"     <li>",
"      There was no difference in the weighted means of carotid IMT measurements from 12 studies comparing HIV-infected patients with or without protease inhibitor exposure.",
"     </li>",
"     <li>",
"      There was evidence of selection bias, with small studies showing an effect of HIV infection and larger studies showing lack of difference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the limitations of the meta-analysis, several subsequent large observational studies supported its findings and reported even larger increases in IMT with HIV infection. In one cross-sectional study of 433 HIV-infected patients and 5749 controls without pre-existing coronary artery disease, the mean difference in the internal carotid artery IMT was 0.148 mm (95% CI 0.113-0.263) after adjusting for demographics (age, race) and traditional cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/3\">",
"     3",
"    </a>",
"    ]. In another study of 300 HIV-infected and 47 uninfected individuals, a similar increase in the IMT at the internal carotid artery and a higher prevalence of carotid artery plaque (50 versus 23 percent) was observed with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/4\">",
"     4",
"    </a>",
"    ]. Moreover, after a mean follow-up of 2.4 years, progression of IMT, particularly at the bifurcation of the carotid, was faster in the setting of HIV infection.",
"   </p>",
"   <p>",
"    Fewer studies have evaluated coronary artery calcification, which is detected by electron beam computed tomography, in HIV-infected patients. In the meta-analysis above, there was no difference in coronary artery calcification between HIV-infected and uninfected patients in the pooled results from five studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/2\">",
"     2",
"    </a>",
"    ]. However, subsequent studies using computed tomography angiography to assess overall plaque burden have reported a higher prevalence among HIV-infected patients compared with uninfected patients with similar Framingham risk scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. On further analysis, the higher plaque burden was due to an increase in noncalcified plaque, which may be more likely to rupture.",
"   </p>",
"   <p>",
"    Evidence of increased subclinical atherosclerosis among HIV-infected elite controllers compared with uninfected controls has also been observed, suggesting that an increased risk of atherosclerosis can occur in the absence of antiretroviral therapy, detectable viremia, or overt immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25650733\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF VASCULAR DISEASE IN HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of atherosclerosis that underlies cardiovascular disease and events is a complicated and multifactorial process that involves inflammation and immune dysregulation, endothelial dysfunction, plaque rupture, as well as the traditional risk factors of hypertension, diabetes, dyslipidemia, and smoking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/17/27930?source=see_link\">",
"     \"Pathogenesis of atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This section discusses markers of abnormalities of inflammation, endothelial function, and coagulation that have been associated both with HIV infection as well as with progression to atherosclerosis or cardiovascular events in the general population. The prevalence of traditional risk factors in HIV-infected patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link&amp;anchor=H2957187#H2957187\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\", section on 'Prevalence of traditional cardiovascular risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1593221\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation plays a pivotal role in the development of atherosclerosis in general and is an area of active research with regards to HIV infection. Active inflammation may adversely affect endothelial cells and promote a prothrombotic environment that leads to atherosclerosis and plaque rupture. HIV infection has been linked to several markers of inflammation, including C-reactive protein and interleukin-6, which in turn have been associated with cardiovascular events. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111728149\">",
"    <span class=\"h3\">",
"     Imaging studies to detect inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Through positron emission tomography (PET) imaging, arterial inflammation can be detected by increased uptake of a radiolabeled glucose analog, fluorodeoxyglucose (FDG), in blood vessels. In one study of 27 HIV-infected patients (mean age, 52 years) on antiretroviral therapy and without known cardiac disease, PET imaging was performed and compared with the findings in HIV-uninfected patients who underwent PET imaging for other reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/15\">",
"     15",
"    </a>",
"    ]. Arterial inflammation in the aorta among HIV-infected patients was higher compared with HIV-uninfected patients who also had no known cardiac disease and were matched by age, sex, and Framingham risk score but was similar to that seen in sex-matched HIV-uninfected patients (mean age, 69 years) who had known atherosclerotic disease. Although aortic inflammation was not associated with levels of C-reactive protein and D-dimer, it did correlate with sCD163, a soluble marker of monocytes and macrophage that has been associated with atherosclerosis in HIV-uninfected populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111728157\">",
"    <span class=\"h3\">",
"     Soluble markers of inflammation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1593279\">",
"    <span class=\"h4\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;C-reactive protein (CRP) is the most extensively studied of numerous inflammatory biomarkers potentially linked to underlying atherosclerosis in the general population, among whom elevations in CRP are associated with an increased risk of cardiovascular events independent of traditional risk factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV infection, particularly in men, has been associated with increased CRP levels when compared with uninfected controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/16\">",
"     16",
"    </a>",
"    ]. Furthermore, in a study of 922 HIV-infected patients followed for five years, a high CRP was independently associated with increased overall mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/17\">",
"     17",
"    </a>",
"    ]. With regards to the specific morbidity of cardiovascular disease, the association between CRP levels and myocardial infarction (MI) risk in HIV-infected patients was evaluated in a study of a large hospital database that included 487 HIV-infected and 69,870 HIV-uninfected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/18\">",
"     18",
"    </a>",
"    ]. High CRP (any value exceeding the upper limit of normal of the standard assay or any value in the highest quantile of the high sensitivity CRP assay) was found more frequently among HIV-infected patients (59 versus 39 percent). In an adjusted model controlling for age, sex, race, hypertension, diabetes and dyslipidemia, the risk for acute myocardial infarction was increased more than fourfold among patients with HIV infection and elevated CRP when compared with patients with neither risk factor. There was no association between CRP level and HIV viral load or CD4 cell count, but protease inhibitor use was associated with high CRP levels.",
"   </p>",
"   <p>",
"    The effect on antiretroviral therapy (ART) in general on CRP is unclear, with some studies showing an increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/19\">",
"     19",
"    </a>",
"    ] and others showing a decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/20\">",
"     20",
"    </a>",
"    ]. Changes in CRP level may depend on the particular agent used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In a study of 244 patients who had been randomly assigned to initiate one of four ART regimens, increases in CRP at weeks 24 and 96 were observed with regimens containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    , particularly when used with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , in contrast to stable levels with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/21\">",
"     21",
"    </a>",
"    ]. This finding was notable because of an apparent increase in myocardial infarction risk seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    in a large cohort of HIV-infected patients (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link&amp;anchor=H742816#H742816\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\", section on 'Abacavir'",
"    </a>",
"    ). However, this study did not analyze the association of such changes in CRP with cardiovascular events, and in fact, the two participants who experienced a myocardial infarction during the study period were receiving tenofovir-emtricitabine and efavirenz.",
"   </p>",
"   <p>",
"    It is unclear whether the association between CRP and cardiovascular events in HIV-infected individuals differs from that among the uninfected population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1593286\">",
"    <span class=\"h4\">",
"     Il-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of the proinflammatory cytokine IL-6 is thought to have a direct causal role in the development of CHD among the general population (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H835935#H835935\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Interleukin-6'",
"    </a>",
"    ) and have been observed in patients with HIV infection, particularly with more advanced disease. In a study of 1525 HIV-infected veterans, there was no overall difference in prevalence of elevated IL-6 compared with 843 uninfected controls after controlling for age and race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/24\">",
"     24",
"    </a>",
"    ]. However, there was a greater association with elevated IL-6 levels compared with the uninfected in the setting of an HIV viral load &ge;500",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (OR 1.54, 95% CI 1.14-2.09) or a CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    (OR 2.25, 95% CI 1.60-3.16). Furthermore, in post-hoc analyses of participants in the SMART trial, which evaluated ART continuation versus treatment interruption based on CD4 cell count, elevated levels of IL-6 were associated with HIV RNA viremia, cardiovascular events, and all cause-mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A subsequent small study suggested that elevations in IL-6 were associated with endothelial dysfunction as reflected by changes in small artery elasticity and endothelial adhesion molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the initial hypothesis that the apparent association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and cardiovascular events may be related to an increase in inflammation with initiation of the drug, subsequent studies evaluating markers of inflammation, such as IL-6, have not supported it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/21,28,29\">",
"     21,28,29",
"    </a>",
"    ]. In an analysis of participants from a study which had previously shown that patients randomly assigned to a regimen containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    had a higher rate of cardiovascular events compared with those assigned to a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    regimen, there was no difference between the treatment arms in the change in multiple markers of inflammation, including IL-6, from baseline to week 12 of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/28\">",
"     28",
"    </a>",
"    ]. Another study showed similar decreases in IL-6 levels at week 96 among patients starting treatment regimens containing abacavir-lamivudine versus tenofovir-emtricitabine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10000555\">",
"    <span class=\"h2\">",
"     Endothelial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction is an initial step in atherosclerosis and has been associated with an increased incidence of cardiovascular events in HIV-uninfected populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/30\">",
"     30",
"    </a>",
"    ]. Several studies have suggested that both HIV infection and its treatment may promote vascular and endothelial dysfunction. These studies have indirectly measured endothelial function through arterial pulse wave testing and flow dynamics and serum markers. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10000562\">",
"    <span class=\"h3\">",
"     Arterial dynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a clinical trial of treatment-na&iuml;ve subjects randomly assigned to initiate various ART regimens, there was a rapid and significant improvement in flow-mediated dilation of the brachial artery, a measure of endothelial function, during the first 24 weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/31\">",
"     31",
"    </a>",
"    ]. This improvement in flow-mediated dilation was seen regardless of regimen, suggesting that suppression of HIV, and not the specific drugs themselves, led to improved endothelial function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/32\">",
"     32",
"    </a>",
"    ]. Another study used noninvasive measurement of radial pulse waveforms to assess large and small artery elasticity in 32 treatment-naive HIV-seropositive individuals and 30 HIV-seronegative individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/33\">",
"     33",
"    </a>",
"    ]. After adjusting for risk factors, including the Framingham 10-year cardiovascular disease risk score, those with HIV infection demonstrated significantly less elasticity in both large and small arteries when compared with the HIV-negative group. These data suggest that chronic HIV infection, independent of its pharmacologic treatment, induces alterations of endothelial function.",
"   </p>",
"   <p>",
"    However, there is evidence for endothelial dysfunction in HIV-infected patients on therapy as well. Increased pulse wave velocity, which may be an early marker for atherosclerosis, has been noted in two small studies of HIV-infected patients taking ART compared with HIV-negative controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Cumulative duration of ART exposure was associated with an incremental increase in velocity, supporting a role of HIV therapy in the pathogenesis of endothelial dysfunction.",
"   </p>",
"   <p>",
"    Certain antiretroviral agents may be more highly associated with abnormal endothelial function than others. In HIV-negative individuals, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    was associated with endothelial dysfunction, independent of drug-induced alterations in blood pressure or lipid profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/36\">",
"     36",
"    </a>",
"    ]. However, in contrast to the dramatic impairment seen with indinavir,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and lopinavir did not induce endothelial dysfunction in 18 healthy subjects in another small study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/37\">",
"     37",
"    </a>",
"    ]. These data suggest that any endothelial dysfunction related to protease inhibitors is drug specific and not class specific.",
"   </p>",
"   <p>",
"    One small study of 61 patients on ART suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    may be associated with endothelial dysfunction as assessed by flow-mediated dilation, which may underlie the observed increased risk of myocardial infarction among abacavir-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63640431\">",
"    <span class=\"h3\">",
"     Plasma markers of endothelial function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective cohort study of 56 HIV-infected patients starting an ART regimen based on either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, serum markers of endothelial dysfunction (eg, monocyte chemoattractant protein, P-selectin, vascular cell adhesion molecule, and von Willebrand factor) declined similarly with either treatment approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/39\">",
"     39",
"    </a>",
"    ]. In contrast, increased levels of these markers were observed at baseline and 3, 6, and 12 months of follow-up in a control cohort of 10 untreated HIV-infected patients with CD4 cell counts &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Compared with HIV-infected patients, healthy controls had significantly lower levels of all measured markers at every time point.",
"   </p>",
"   <p>",
"    Similarly, in a subset analysis of HIV-infected patients randomly assigned to start ART immediately (n = 134) or to delay ART initiation until warranted by HIV disease progression (n = 114), the levels of asymmetric dimethylarginine (ADMA), an inhibitor of the nitric oxide synthase pathway that reflects endothelial dysfunction and may be an independent risk factor for cardiovascular disease, changed more favorably after 12 months with immediate ART administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/40\">",
"     40",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H1269197#H1269197\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Asymmetrical dimethylarginine'",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    However, other studies have shown that antiretroviral medications also contribute to aberrations in levels of markers of endothelial function, such as soluble endothelial adhesion molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/36,41-44\">",
"     36,41-44",
"    </a>",
"    ]. In one study, plasma P-selectin and t-PA were measured in 60 patients on ART and 60 treatment-na&iuml;ve patients. Significantly higher levels of both markers were found in those taking ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These clinical studies of altered endothelial function in HIV infection are supported by in vitro evidence, which demonstrates that HIV-associated proteins, such as gp120 and Tat (transactivator of viral replication), are toxic to vascular or cardiac cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In an AIDS murine model, vascular smooth muscle tone is reduced as early as the first week after retroviral infection, suggesting vascular dysfunction precedes the onset of significant immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/47\">",
"     47",
"    </a>",
"    ]. This effect may be mediated by vascular endothelial nitric oxide dysregulation and prostacyclin-induced vasodilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10000576\">",
"    <span class=\"h2\">",
"     Abnormalities of coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to endothelial dysfunction, there is also evidence of a dysregulation of coagulation and fibrinolysis, which have been linked to cardiovascular disease in the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23193?source=see_link\">",
"     \"Fibrinolytic markers and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have described elevated plasma levels of endothelial cell products, including von Willebrand factor and soluble thrombomodulin, and the fibrin degradation product D-dimer in those living with HIV, and these levels are noted to inversely correlate with CD4 counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/24,49,50\">",
"     24,49,50",
"    </a>",
"    ]. A positive correlation has also been noted between HIV viral load and prothrombin fragment in 90 HIV-infected individuals (mean age 38 &plusmn; 9 years, mean CD4 216 &plusmn; 198) not receiving ART, which suggests that increasing levels of viremia may increase the risk for thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moreover, elevated D-dimer levels in the setting of treatment interruption and elevated fibrinogen levels have been associated with increased mortality in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. Additionally, in a case control study of HIV-infected patients who had experienced a cardiovascular event (n = 52) or not (n = 104), D-dimer was independently associated with cardiovascular event risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all changes in markers of coagulation in the setting of HIV infection suggest a hypercoagulable state. In a study of 278 HIV-infected men, levels of antithrombin were higher and levels of a functional measure of thrombin generation were lower compared with 39 uninfected controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, it is unclear what the impact of antiretroviral therapy is on coagulation. One study of 1131 HIV-infected patients and 281 controls found that increased levels of fibrinogen were associated with protease inhibitor use, whereas non-nucleoside reverse transcriptase inhibitor use was associated with lower fibrinogen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10000612\">",
"    <span class=\"h2\">",
"     Other factors associated with atherosclerosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10000627\">",
"    <span class=\"h3\">",
"     Viral co-infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of ongoing inflammation secondary to the presence of other chronic viral infections may also promote the development of atherosclerosis and subclinical cardiovascular disease in HIV-infected patients. In a study of 93 HIV-infected patients (91 percent men and 94 percent on ART), greater CD4 and CD8 T cell responses against cytomegalovirus (CMV) were independently associated with increased carotid intima media thickness (IMT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/55\">",
"     55",
"    </a>",
"    ]. In a separate study of 601 HIV-infected women with positive CMV IgG serology, higher levels of CMV IgG were independently associated with carotid artery stiffness but not carotid IMT as measured by carotid ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/56\">",
"     56",
"    </a>",
"    ]. No such association was seen in 90 uninfected controls matched for age and race. A possible role of ART in mediating the relationship between CMV response and vascular disease was suggested by the finding that CMV IgG levels were associated with the prevalence of carotid artery lesions only among HIV-infected patients who had viral suppression on ART, not those who were untreated or continued to be viremic despite ART. Although these studies examined only indirect markers of both CMV-associated inflammation and cardiovascular disease, they nonetheless provide preliminary evidence to suggest a role of CMV infection in the pathogenesis of atherosclerosis in HIV-infected patients.",
"   </p>",
"   <p>",
"    Other viruses that have been implicated in the development of subclinical cardiovascular disease in HIV-infected patients include herpes simplex virus 2 (HSV-2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/57\">",
"     57",
"    </a>",
"    ]. Coinfection with Hepatitis C virus (HCV) has been linked to endothelial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/58\">",
"     58",
"    </a>",
"    ] and modulates known risk factors for cardiovascular disease in HIV-infected patients, but does not appear to increase the risk of myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link&amp;anchor=H2959230#H2959230\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\", section on 'Hepatitis C virus coinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10000634\">",
"    <span class=\"h3\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 674 HIV-infected black patients without known cardiovascular disease, vitamin D deficiency (level &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    was more prevalent among the 64 patients with significant coronary stenosis on computed tomography angiography (31 percent) compared with the 610 without stenosis (19 percent) and was independently associated with this finding on adjusted analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/59\">",
"     59",
"    </a>",
"    ]. Vitamin D deficiency in HIV-infected patients has also been linked to other markers of subclinical cardiovascular disease, including carotid intima media thickness and brachial artery flow-mediated dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is unclear whether replacing vitamin D will have a cardiovascular benefit. In a trial of HIV-infected adults with viral suppression on antiretroviral therapy who had vitamin D levels &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    there was no significant change in brachial artery flow-mediated dilation at 12 weeks in the 30 patients randomly assigned to daily supplementation with 4000 international units cholecalciferol or in the 15 patients assigned to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40392/abstract/63\">",
"     63",
"    </a>",
"    ]. Furthermore, other than a small decrease in the IL-6 level in those taking supplementation, there were no differences between the two groups in changes in other markers of endothelial dysfunction, coagulation function, or inflammation. Of note, the patients in the supplementation group experienced a mere 5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    increase in the vitamin D level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1592992\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular disease has emerged as an important cause of death in HIV-infected patients, as illustrated by clinical studies evaluating such hard endpoints as stroke or myocardial infarctions. Studies that rely on measures of subclinical atherosclerosis, such as carotid intima media thickness and coronary artery plaque on imaging, also suggest an increased prevalence of disease in HIV-infected patients compared with the uninfected. (See",
"      <a class=\"local\" href=\"#H10000548\">",
"       'Subclinical atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV infection is associated with elevated markers of inflammation, endothelial dysfunction, and altered coagulation, all of which have been shown to contribute to cardiovascular disease. The effect of antiretroviral therapy on these markers is less clear. (See",
"      <a class=\"local\" href=\"#H1593221\">",
"       'Inflammation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10000555\">",
"       'Endothelial dysfunction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10000576\">",
"       'Abnormalities of coagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional cardiac risk factors, such as dyslipidemia, diabetes, smoking, and hypertension, also contribute directly to the pathogenesis of cardiovascular disease. Their prevalence in HIV-infected patients is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link&amp;anchor=H2957187#H2957187\">",
"       \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\", section on 'Prevalence of traditional cardiovascular risk factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/1\">",
"      Bots ML, Baldassarre D, Simon A, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J 2007; 28:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/2\">",
"      Hulten E, Mitchell J, Scally J, et al. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart 2009; 95:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/3\">",
"      Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/4\">",
"      Hsue P, Scherzer R, Hunt PW, et al. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc 2012; 1:jah3-:e000422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/5\">",
"      Merci&eacute; P, Thi&eacute;baut R, Aurillac-Lavignolle V, et al. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005; 6:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/6\">",
"      Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007; 21:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/7\">",
"      Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/8\">",
"      Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/9\">",
"      Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/10\">",
"      Bongiovanni M, Casana M, Cicconi P, et al. Predictive factors of vascular intima media thickness in HIV-positive subjects. J Antimicrob Chemother 2008; 61:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/11\">",
"      Fitch KV, Looby SE, Rope A, et al. Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS 2013; 27:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/12\">",
"      Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/13\">",
"      Fitch KV, Lo J, Abbara S, et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr 2010; 55:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/14\">",
"      Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/15\">",
"      Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/16\">",
"      Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/17\">",
"      Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/18\">",
"      Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/19\">",
"      Aslangul E, Fellahi S, Assoumou LK, et al. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS 2011; 25:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/20\">",
"      Arildsen H, S&oslash;rensen KE, Ingerslev JM, et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/21\">",
"      Hileman CO, Wohl DA, Tisch DJ, et al. Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. AIDS Res Hum Retroviruses 2012; 28:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/22\">",
"      Mart&iacute;nez E, D'Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012; 26:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/23\">",
"      Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205 Suppl 3:S375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/24\">",
"      Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/25\">",
"      Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/26\">",
"      Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/27\">",
"      Baker J, Quick H, Hullsiek KH, et al. Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med 2010; 11:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/28\">",
"      Martin A, Amin J, Cooper DA, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/29\">",
"      Palella FJ Jr, Gange SJ, Benning L, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/30\">",
"      Sch&auml;chinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/31\">",
"      Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/32\">",
"      Murphy R, Costagliola D. Increased cardiovascular risk in HIV infection: drugs, virus and immunity. AIDS 2008; 22:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/33\">",
"      Baker JV, Duprez D, Rapkin J, et al. Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr 2009; 52:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/34\">",
"      van Wijk JP, de Koning EJ, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006; 47:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/35\">",
"      Schillaci G, De Socio GV, Pirro M, et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol 2005; 25:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/36\">",
"      Shankar SS, Dub&eacute; MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/37\">",
"      Dub&eacute; MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008; 47:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/38\">",
"      Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/39\">",
"      Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009; 23:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/40\">",
"      Baker JV, Neuhaus J, Duprez D, et al. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 2012; 60:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/41\">",
"      de Gaetano Donati K, Rabagliati R, Tumbarello M, et al. Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS 2003; 17:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/42\">",
"      Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr 2005; 40:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/43\">",
"      Fu W, Chai H, Yao Q, Chen C. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr 2005; 39:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/44\">",
"      de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/45\">",
"      Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci U S A 2001; 98:10142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/46\">",
"      Paladugu R, Fu W, Conklin BS, et al. Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/47\">",
"      Baliga RS, Chaves AA, Jing L, et al. AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol 2005; 289:H1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/48\">",
"      Martin S, Tesse A, Hugel B, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 2004; 109:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/49\">",
"      Seigneur M, Constans J, Blann A, et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997; 77:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/50\">",
"      Blann AD, Seigneur M, Constans J, et al. Soluble P-selectin, thrombocytopenia and von Willebrand factor in HIV infected patients. Thromb Haemost 1997; 77:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/51\">",
"      Karmochkine M, Ankri A, Calvez V, et al. Plasma hypercoagulability is correlated to plasma HIV load. Thromb Haemost 1998; 80:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/52\">",
"      Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/53\">",
"      Hsue PY, Scherzer R, Grunfeld C, et al. HIV infection is associated with decreased thrombin generation. Clin Infect Dis 2012; 54:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/54\">",
"      Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/55\">",
"      Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/56\">",
"      Parrinello CM, Sinclair E, Landay AL, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis 2012; 205:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/57\">",
"      Hechter RC, Budoff M, Hodis HN, et al. Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study. Atherosclerosis 2012; 223:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/58\">",
"      de Castro IF, Micheloud D, Berenguer J, et al. Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. AIDS 2010; 24:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/59\">",
"      Lai H, Gerstenblith G, Fishman EK, et al. Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis 2012; 54:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/60\">",
"      Choi AI, Lo JC, Mulligan K, et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis 2011; 52:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/61\">",
"      Shikuma CM, Seto T, Liang CY, et al. Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses 2012; 28:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/62\">",
"      Ross AC, Judd S, Kumari M, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther 2011; 16:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40392/abstract/63\">",
"      Longenecker CT, Hileman CO, Carman TL, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther 2012; 17:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83686 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40392=[""].join("\n");
var outline_f39_28_40392=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1592992\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10000541\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10000548\">",
"      SUBCLINICAL ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25650733\">",
"      PATHOGENESIS OF VASCULAR DISEASE IN HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1593221\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111728149\">",
"      - Imaging studies to detect inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111728157\">",
"      - Soluble markers of inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1593279\">",
"      C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1593286\">",
"      Il-6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10000555\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10000562\">",
"      - Arterial dynamics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63640431\">",
"      - Plasma markers of endothelial function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10000576\">",
"      Abnormalities of coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10000612\">",
"      Other factors associated with atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10000627\">",
"      - Viral co-infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10000634\">",
"      - Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1592992\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23193?source=related_link\">",
"      Fibrinolytic markers and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/17/27930?source=related_link\">",
"      Pathogenesis of atherosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_28_40393="Screening for osteoporosis";
var content_f39_28_40393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40393/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40393/contributors\">",
"     Michael Kleerekoper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40393/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40393/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40393/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/28/40393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/28/40393/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/28/40393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a common disease that is characterized by low bone mass, microarchitectural disruption, and skeletal fragility, resulting in an increased risk of fracture. The goal of screening is to identify persons at increased risk of sustaining a low trauma fracture and who would benefit from intervention to minimize that risk.",
"   </p>",
"   <p>",
"    Screening for fracture risk involves appropriate history, physical examination, standard biochemical and hematologic studies, and measurement of bone mineral density (BMD). The clinical history should include inquiring about possible secondary causes of bone loss, including use of medications with potential adverse effects on bone health and family history of osteoporosis. A widespread approach to BMD screening alone has not been universally adopted, in part due to cost and questions regarding the efficacy of a broad population screening policy. The issues surrounding screening for osteoporosis in postmenopausal women and men are reviewed here. Controversies surrounding screening for osteoporosis in premenopausal women are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detailed information about diagnosis, prevention, and treatment of osteoporosis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is characterized by low bone mass, microarchitectural disruption, and increased skeletal fragility. In addition, the World Health Organization (WHO) has defined osteoporosis based upon dual-energy x-ray absorptiometry (DXA) measurements (",
"    <a class=\"graphic graphic_table graphicRef74190 \" href=\"mobipreview.htm?11/28/11723\">",
"     table 1",
"    </a>",
"    ). The relative risk of fracture increases as BMD decreases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'T-score'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link\">",
"     \"Overview of dual-energy x-ray absorptiometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The burden of suffering associated with osteoporosis is related to the increased incidence of fractures in individuals with low bone mass and microarchitectural deterioration. Fragility fractures are defined as fractures that occur following a fall from standing height or less or with no trauma. Although the greatest relative risk of fracture is in individuals with osteoporosis, the absolute number of fractures in those with BMD T-scores in the low bone mass (osteopenia) range is the same or greater than in those with T-scores in the osteoporosis range. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Assessment of fracture risk'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There were an estimated nine million osteoporotic fractures worldwide in 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/1\">",
"     1",
"    </a>",
"    ]. Some estimates predict a continued increase in the number of hip fractures over the next 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/2\">",
"     2",
"    </a>",
"    ]. However, other epidemiologic studies suggest a changing trend [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In one study from Finland, review of a national discharge registry revealed a decline in hip fracture rates between 1997 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/5\">",
"     5",
"    </a>",
"    ]. Possible reasons for the decline include a healthier aging population, improved functional ability, increased body weight, and greater use of calcium, vitamin D, and pharmacologic therapy for osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF FRACTURE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for osteoporosis involves fracture risk assessment and measurement of BMD. Most fractures occur in women and men who do not have osteoporosis by DXA criteria. Individuals with osteoporosis are at the highest relative risk of fracture, but there are more fractures in patients with low bone mass or osteopenia (T-score between -1.0 and -2.5) because there are so many more patients in this category. Therefore, assessment of risk factors that are independent of BMD is important for fracture prediction. Validated risk factors that are independent of BMD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Previous fracture",
"     </li>",
"     <li>",
"      Long-term glucocorticoid therapy",
"     </li>",
"     <li>",
"      Low body weight (less than 58 kg [127 lb])",
"     </li>",
"     <li>",
"      Family history of hip fracture",
"     </li>",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Excess alcohol intake",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most robust non-BMD risk factors are age and previous low trauma",
"    <strong>",
"    </strong>",
"    fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These risk factors are easily discernible from a routine history and physical examination; taken together they are highly predictive of low bone density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/8\">",
"     8",
"    </a>",
"    ] and future hip fracture, even in the absence of bone density measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/9\">",
"     9",
"    </a>",
"    ]. Although clinical risk factors are predictive of bone density and fracture risk, they may not be as useful for predicting response to therapy for osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend assessing risk factors for fracture in all adults, especially postmenopausal women, men over 60, and in any individual who experiences a fragility or low-trauma fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factor screening instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several osteoporosis risk assessment instruments have been developed to improve the selection of women and men for measurement of BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. However, none of the tools were very specific, and most were not validated in other cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2008, a WHO task force introduced a Fracture Risk Assessment Tool (",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     FRAX",
"    </a>",
"    ), which estimates the 10-year probability of hip fracture or major osteoporotic fractures combined (hip, spine, shoulder, or wrist) for an untreated woman or man using easily obtainable clinical risk factors for fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ) with or without information on bone mineral density. FRAX has been validated in 40 cohorts (over one million patient years). The technical aspects of FRAX are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H4#H4\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Fracture risk assessment tool'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When combined with country-specific economic analyses, FRAX can provide guidance for both BMD testing (assessment threshold) and treatment (intervention threshold). In countries with limited or no access to DXA, the FRAX algorithm can potentially be used to identify individuals in whom measurement of BMD would influence management decisions. As an example, measurement of BMD may be indicated in those with an intermediate fracture probability, in whom the selective addition of BMD testing may result in intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, in those with high fracture probability, intervention may be justified without BMD measurement. Country-specific economic analyses are required to develop assessment thresholds, ie, the fracture probability at which BMD testing is cost-effective. Until such economic analyses are available, we do not suggest using the FRAX algorithm to identify individuals for bone density testing.",
"   </p>",
"   <p>",
"    The use of the FRAX algorithm to define intervention thresholds is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H5#H5\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical application of fracture risk assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of osteoporosis in men\", section on 'Candidates for therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Biochemical markers of bone remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical markers that reflect the overall rates of bone resorption and formation are currently available clinically and have been used extensively in research to help understand the pathogenesis of osteoporosis and responses to therapy. The mean values of these markers are generally higher in patients with osteoporosis than in matched normal subjects, but there is substantial overlap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Measurement of these markers is not helpful in deciding for or against bone density measurements. However, markers can provide information about fracture risk beyond that available from measurements of BMD and could conceivably influence a decision for or against pharmacologic intervention (",
"    <a class=\"graphic graphic_figure graphicRef77540 \" href=\"mobipreview.htm?8/59/9150\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, most studies indicate that pharmacologic intervention will reduce fracture risk independent of the initial marker value. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BONE DENSITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone density measurements are used in conjunction with fracture risk assessment for osteoporosis screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/22\">",
"     22",
"    </a>",
"    ]. Low BMD is associated with increased risk of fracture, regardless of the technique used for measurement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H6#H6\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Methods of measurement of BMD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dual-energy x-ray absorptiometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual energy x-ray absorptiometry (DXA) is the most widely used method for measuring BMD because it gives very precise measurements at clinically relevant skeletal sites (ie, those with major clinical consequences when a fracture occurs). The major disadvantages of DXA are that the machine is large (not portable) and expensive, and that it uses ionizing radiation, albeit in a very low dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link\">",
"     \"Overview of dual-energy x-ray absorptiometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many studies have demonstrated that low bone density (DXA) at any site can predict osteoporotic fracture, although hip measurements are superior to spine in predicting hip as well as overall osteoporotic fracture. DXA and fracture prediction are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H7#H7\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Dual-energy x-ray absorptiometry (DXA)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Quantitative computerized tomography (QCT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;QCT measures volumetric bone density of the spine and hip and can analyze cortical and trabecular bone separately. This method is quite useful in clinical research and may be used in individual patients to follow therapeutic responses to therapy, where large changes may be observed. However, it is not recommended for screening, largely because the application of T-scores to predict the risk of fracture has not been validated with QCT. In addition, this method is more costly and results in greater exposure to radiation than DXA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H6#H6\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Methods of measurement of BMD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Peripheral measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high cost and lack of portability of DXA, other techniques to measure peripheral sites have been developed. These include ultrasound, peripheral dual-energy x-ray absorptiometry (pDXA), x-ray absorptiometry, and peripheral quantitative computed tomography (pQCT) of the heel, radius, or hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/22\">",
"     22",
"    </a>",
"    ]. The WHO criteria for the diagnosis of osteoporosis are based upon BMD measured by DXA and, therefore, do not apply to these other technologies. However, these technologies can be used to predict fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H6#H6\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Methods of measurement of BMD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative ultrasound appears to be a good predictor of fractures in men and women, and is at least as good as clinical risk factors for identifying patients at high risk for osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H11#H11\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Quantitative ultrasonography (QUS)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a limitation of ultrasound is that it does not reliably exclude or confirm DXA-determined osteoporosis. A meta-analysis of 25 studies that evaluated the sensitivity and specificity of calcaneal ultrasound for identifying patients with DXA T-scores &le;-2.5 concluded that currently used ultrasound cutoff thresholds do not have sufficiently high sensitivity or specificity to definitively exclude or confirm DXA-diagnosed osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another major limitation to using quantitative ultrasound as a screening tool is that the criteria for diagnosing osteoporosis and recommending treatment based upon ultrasound are not yet well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Furthermore, ultrasound cannot reliably be used to follow patients who are treated for osteoporosis because of limited precision and a slow rate of change of bone mass at peripheral sites. Thus, most individuals with a high-risk ultrasound finding will need a confirmatory DXA both to determine the need for treatment based upon well-established guidelines, and as a baseline for monitoring therapy. A cost-effectiveness analysis using ultrasound to determine which women need DXA did not show this approach to be more cost-effective than a strategy using DXA alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, although ultrasound has some utility for fracture prediction, because of the inability to apply ultrasound and other peripheral measurements to current diagnostic and treatment standards, and to monitor response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/27\">",
"     27",
"    </a>",
"    ], we continue to recommend DXA for screening purposes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In regions without access to DXA, however, peripheral measurements using a validated technique (such as ultrasound) for fracture risk assessment is acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Skeletal site to measure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although overall fracture risk can be predicted by measurement or estimation of BMD at many skeletal sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], the risk for fracture at a particular skeletal site is best estimated by measuring BMD at that skeletal site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. As an example, hip BMD is superior to BMD measured at other skeletal sites in predicting hip fracture. Therefore, since hip fracture is often associated with significant morbidity and mortality compared with other fractures, DXA of the hip is generally regarded as the best site for diagnosis of osteoporosis. In contrast, the lumbar spine is often considered the best skeletal site to monitor because it shows less variability and can detect responses to therapy earlier than hip BMD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H7#H7\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Dual-energy x-ray absorptiometry (DXA)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H16#H16\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Skeletal site to measure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best site to measure for osteoporosis screening is controversial. Measurements from different sites (spine, hip, forearm) are often discordant with regard to the WHO diagnostic classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. Thus, when measurements of different skeletal sites are performed, the diagnosis of osteoporosis is based upon the lowest T-score for BMD assessed at one of these sites. Measuring more than one site generally increases the number of individuals categorized as osteoporotic. A meta-analysis of several population-based cohort studies showed that there was no advantage in risk prediction when measuring multiple sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, assessment of multiple sites does not appear to improve fracture prediction.",
"   </p>",
"   <p>",
"    Nevertheless, in younger postmenopausal women with risk factors for fracture, we suggest DXA measurements of both the spine and hip because early menopause is associated with greater BMD loss at the spine than the hip. In addition, interference from osteophytes and vascular calcifications on the spine measurement is usually minimal in women less than 65 years of age. In contrast, spinal osteophytes are common in aging women and men, which interferes with the assessment of BMD at this site. In this setting, measurement of hip BMD alone could be sufficient.",
"   </p>",
"   <p>",
"    However, if pharmacologic therapy is planned, measurement of spine BMD might be useful for monitoring response to therapy. In the presence of degenerative changes of the spine, bone mineral density can be monitored at another skeletal site, such as the hip or radius, although the sensitivity for detecting changes at these locations is lower.",
"   </p>",
"   <p>",
"    Some authorities have a somewhat different approach, using the hip as the preferred site for measuring BMD, regardless of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/15,33\">",
"     15,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Candidates for BMD testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several strategies for incorporating BMD measurements into osteoporosis screening programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/36\">",
"     36",
"    </a>",
"    ]. These include screening all individuals over a certain age (when fracture risk increases), screening only those women and men over a certain age with clinical risk factors for fracture, or screening those with clinical risk factors who are close to an intervention threshold and in whom the selective addition of BMD testing may result in intervention.",
"   </p>",
"   <p>",
"    We suggest BMD testing (DXA) in women 65 years of age and older and in postmenopausal women younger than 65 years of age with clinical risk factors for fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ). This recommendation is based upon the findings of an increased incidence of fracture that occurs in conjunction with low BMD after age 65 years and clinical trial data demonstrating a reduction in fracture when these women are treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Effectiveness of early detection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of data supporting routine bone mineral density testing in men above a certain age, we suggest not performing routine testing in men. However, we do recommend measurement of BMD in men with clinical manifestations of low bone mass, such as radiographic osteopenia, history of low trauma fractures, and loss of more than 1.5 inches in height, as well as in those with risk factors for fracture, such as long-term glucocorticoid therapy, androgen deprivation therapy for prostate cancer, hypogonadism, primary hyperparathyroidism, and intestinal disorders (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical risk factor assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and etiology of osteoporosis in men\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BMD screening recommendations for premenopausal women are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Recommendations by expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States and Canada, the majority of groups recommend BMD assessment in postmenopausal women 65 years and older regardless of risk factors (",
"    <a class=\"graphic graphic_table graphicRef62866 \" href=\"mobipreview.htm?0/52/846\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/37-45\">",
"     37-45",
"    </a>",
"    ]. BMD screening recommendations for men and for women younger than 65 years vary (",
"    <a class=\"graphic graphic_table graphicRef62866 \" href=\"mobipreview.htm?0/52/846\">",
"     table 3",
"    </a>",
"    ). The United States Preventive Services Task Force (USPSTF) found insufficient evidence to make a recommendation for screening men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. The USPSTF recommends BMD screening in women younger than 65 years whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors for fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. The USPSTF used the World Health Organization Fracture Risk Assessment (FRAX) algorithm to select a threshold above which bone density testing is recommended. Although this approach to bone density screening may have merit, the selected threshold (9.3 percent) was not subject to cost-effectiveness analysis nor validated in any patient population. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factor screening instruments'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other groups, such as the National Osteoporosis Foundation (NOF), the International Society for Clinical Densitometry (ISCD), and the Endocrine Society, recommend BMD testing for all men older than 70 years, and in men and women 50 to 70 years when risk factors are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/37,38,46\">",
"     37,38,46",
"    </a>",
"    ]. The Canadian Osteoporosis Society recommends testing in men and women 50 to 64 years with clinical risk factors for fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/43\">",
"     43",
"    </a>",
"    ], whereas the American College of Physicians recommends measurement of BMD in men who are at increased risk for osteoporosis (including men &gt;70 years of age) and are candidates for drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, some European groups recommend BMD screening based upon risk stratification, ie, the decision to measure BMD is based upon age-specific fracture probability thresholds calculated using FRAX (without BMD information) or other risk assessment tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/36,45\">",
"     36,45",
"    </a>",
"    ]. Only women and men with a fracture probability near an intervention threshold, in whom the selective addition of BMD testing may result in intervention, are referred for BMD testing (",
"    <a class=\"graphic graphic_table graphicRef62866 \" href=\"mobipreview.htm?0/52/846\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/36,48-50\">",
"     36,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF EARLY DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard that would support screening for osteoporosis is the demonstration in a well-designed randomized trial that screening reduces fracture risk. Determining the relative effectiveness of screening would also depend upon the quality of the BMD measurements and the risk factor analysis, the ability of the clinician to prescribe appropriate treatment, and the compliance of the patient.",
"   </p>",
"   <p>",
"    In the only published trial, 4800 postmenopausal women (aged 45 to 54 years) were randomly assigned to osteoporosis screening (BMD measurement) or no screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/51\">",
"     51",
"    </a>",
"    ]. Follow-up data were obtained via questionnaire. After a mean of nine years, a greater proportion of screened women reported current or past use of hormone therapy (52 versus 45 percent) or other osteoporosis medications (37 versus 22 percent). In an intention-to-treat analysis, there was a nonsignificant reduction in the incidence of fracture in the screened group (8.8 versus 9.4 percent, HR 0.79, 95% CI 0.60-1.04). Limitations of trial include a low (60 percent) response rate and self-report of hormone therapy (HT) or other osteoporosis medications.",
"   </p>",
"   <p>",
"    Other estimates of the fracture prevention benefits of screening and intervention are largely based upon trials of bisphosphonates that enrolled postmenopausal women who were at high risk for fracture. The fracture benefits noted are not applicable to a screening program because patients were not identified for participation in the trials by screening the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of definitive data, population-based screening remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Arguments supporting screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of arguments to support screening for osteoporosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is a common disease with significant morbidity and mortality and without screening many high-risk patients would go undetected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening through risk factor assessment and bone mineral density (BMD) testing is available to many clinicians in some countries.",
"     </li>",
"     <li>",
"      The risk for most fractures is inversely proportional to BMD (",
"      <a class=\"graphic graphic_figure graphicRef77540 \" href=\"mobipreview.htm?8/59/9150\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/53-60\">",
"       53-60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of effective therapies (both pharmacological and nonpharmacological) are available to reduce fracture risk in patients who are diagnosed with osteoporosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"       \"Treatment of osteoporosis in men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Knowledge of fracture risk, which includes but is not limited to BMD, could improve compliance with both lifestyle changes and pharmacotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Arguments against screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several arguments against widespread screening for osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, the only published randomized trial did not find a significant fracture benefit from screening but had some design limitations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no discrete value for BMD that discriminates clearly between patients who will fracture and those who will not. In addition, many fractures occur in those without osteoporosis by BMD criteria, which decreases the value of using BMD (alone) as a tool for identifying individuals at high risk for fracture.",
"     </li>",
"     <li>",
"      A single measurement indicates only current BMD, not the anticipated rate of bone loss. Other factors may be more important in predicting the risk of fracture than BMD&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Assessment of fracture risk'",
"      </a>",
"      above.) As an example, fall-related risk factors may be more important in predicting hip fracture than BMD since more than 90 percent of hip fractures result from falls onto the greater trochanter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=see_link\">",
"       \"Falls in older persons: Risk factors and patient evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain preventive measures, such as adequate calcium and vitamin D intake, exercise, and smoking cessation, should be recommended regardless of BMD. Furthermore, there is some evidence that women with normal BMD are less likely to follow these preventive measures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The availability of DXA and willingness to pay for healthcare varies from country to country and with differing clinical practices [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of cost-effectiveness analyses of pharmacologic therapy for the primary or secondary prevention of osteoporotic fractures have not been uniform. Cost-effectiveness varies from country to country, but generally increases the later in life that screening and treatment occur, with history of prior vertebral fracture, and with decreasing T-score values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/64-68\">",
"     64-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    in a 70-year-old woman with a T-score of -2.5 and prior vertebral fracture was cost-effective in Sweden, Finland, Belgium, and Spain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/65\">",
"     65",
"    </a>",
"    ]. However, when the same individual did not have a history of prior fracture, similar treatment was cost effective in Sweden only. In another report from the UK, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    was cost effective for primary and secondary prevention of osteoporotic fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/69\">",
"     69",
"    </a>",
"    ]. In addition, alendronate was found to be cost effective in women with low BMD or in women with BMD above the threshold for osteoporosis in the presence of clinical risk factors. In another study, alendronate was noted to be cost-effective, whereas teriparatide was not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in cost-effectiveness among countries are related to differences in health care costs and fracture risks. Use of less expensive pharmacologic intervention, such as generic drugs, would further decrease costs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FOLLOW-UP TO SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In conjunction with osteoporosis screening, individuals require counseling regarding fracture prevention, including lifestyle modification, fall prevention, and possibly pharmacologic intervention.",
"   </p>",
"   <p>",
"    The WHO BMD definitions for osteoporosis and low bone mass are diagnostic thresholds rather than intervention thresholds. Pharmacologic intervention to prevent fracture should be based upon the absolute risk of fracture, using a combination of clinical risk factors and BMD to quantify risk. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Assessment of fracture risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All individuals should be counseled about risk factor reduction (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Assessment of fracture risk'",
"      </a>",
"      above), especially with regard to smoking cessation, limiting alcohol intake, and participating in regular weight-bearing and muscle-strengthening exercise.",
"     </li>",
"     <li>",
"      Adults with low bone mass should be advised to consume at least 1200 mg of calcium per day (total diet plus supplement). Adequate vitamin D intake (diet and supplement) is also essential, but there are conflicting guidelines concerning the",
"      <span class=\"nowrap\">",
"       ideal/optimal",
"      </span>",
"      supplement, with some guidelines recommending 600 int. units as a minimum and others recommending 1000 units. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial laboratory evaluation in individuals with low bone mass (BMD T-score below -1.0) should include standard biochemical and hematologic profiles and a measure of urine calcium (spot fasting or 24-hour) excretion. There is an increasing trend for 25-hydroxyvitamin D measurement, but the cost-effectiveness of this is uncertain. Further recommendations regarding initial evaluation of low bone mass are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"       \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic intervention thresholds based upon BMD and clinical risk factors (",
"      <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"       table 2",
"      </a>",
"      ) are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of osteoporosis in men\", section on 'Candidates for therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Repeat BMD measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the frequency of follow-up BMD testing in women and men who have had an initial screening test are limited. The goal of follow-up testing is to detect low bone density before a major fracture occurs. However, whether rate of bone mineral density (BMD) loss is an independent risk factor for fracture is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/71-75\">",
"     71-75",
"    </a>",
"    ]. In a retrospective cohort study using a database of all clinical BMD results from Manitoba, Canada, 146 women sustained one or more osteoporotic fractures after the second BMD test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/72\">",
"     72",
"    </a>",
"    ]. Compared with women who remained fracture free, women who fractured were older, had lower baseline (T-scores lumbar spine -1.0 versus -1.6 and femoral neck -1.2 versus -1.7, respectively) and final BMD, and a higher prevalence of other risk factors for fracture (ie, glucocorticoid use). However, the annualized percentage change in BMD did not differ in women who did and did not sustain major osteoporotic fractures.",
"   </p>",
"   <p>",
"    In the Study of Osteoporotic Fractures (SOF), a repeat BMD measurement performed a mean of eight years after the initial measurement did not improve the overall predictive value of hip, spine, or nonspine fracture risk in 4124 community dwelling women 65 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/71\">",
"     71",
"    </a>",
"    ]. The mean initial T-score was -1.37. In a subsequent analysis from SOF, 4957 women (67 years and older) who did not have osteoporosis at baseline testing were followed for up to 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/28/40393/abstract/76\">",
"     76",
"    </a>",
"    ]. The interval for 10 percent of participants to make the transition from normal BMD or osteopenia at baseline to osteoporosis (before a hip or clinical vertebral fracture occurred and before initiation of osteoporosis treatment) was estimated. For women with normal (T-score -1.0 or better) or slightly low (T-score -1.01 to -1.49) bone mass at baseline, the interval between baseline testing and the development of osteoporosis was approximately 17 years. For women with moderately low (T-score -1.50 to -1.99) or low (T-score -2.00 to -2.49) bone mass at baseline, the interval was 4.7 and 1.1 years, respectively.",
"   </p>",
"   <p>",
"    These data suggest that healthy women 65 years of age and older who have a screening bone density study and are found to have normal bone density or only slightly low bone mass do not require repeat testing for 17 years, whereas women found to have moderately low or low bone mass at baseline require follow-up bone density testing within one to five years.",
"   </p>",
"   <p>",
"    These results are not applicable to women with osteoporosis (T-scores below -2.5) at baseline, women already receiving osteoporosis treatment, or women younger than 65 years of age at time of first bone density screening. Women younger than 65 years of age with clinical risk factors for fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ) may require more frequent monitoring of bone density, depending upon risk factors.",
"   </p>",
"   <p>",
"    Repeat BMD measurements may be most valuable for individual patients on therapy or to document stability of bone density in untreated patients with underlying clinical factors that might lead to accelerated bone loss.",
"   </p>",
"   <p>",
"    Our approach in women and men without osteoporosis at baseline measurement and who are not candidates for pharmacologic therapy is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the presence of low bone mass (T-score -2.00 to -2.49) at any site or risk factors that may cause ongoing bone loss (eg, glucocorticoid use, hyperparathyroidism), we perform follow-up measurements approximately every two years, as long as risk factors persist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H15#H15\">",
"       \"Management of primary hyperparathyroidism\", section on 'Monitoring'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link&amp;anchor=H23#H23\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Summary and Recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In women 65 years of age and older at baseline screening, with low bone mass (T-score -1.50 to -1.99) at any site, and with no risk factors for accelerated bone loss, we will typically perform a follow-up DXA in three to five years.",
"     </li>",
"     <li>",
"      In women 65 years of age and older at baseline screening, with normal or slightly low bone mass (T-score -1.01 to -1.49), and with no risk factors for accelerated bone loss, we will typically perform a follow-up DXA in 10 to 15 years. A 65-year-old woman with a femoral neck BMD T-score of -1.01 to -1.49 and no clinical risk factors for fracture has a low FRAX-calculated (",
"      <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"       FRAX",
"      </a>",
"      ) 10-year absolute risk of hip fracture (approximately 0.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any properly installed and validated DXA instrument is appropriate for initial BMD measurement. However, to the extent possible, it is essential that all subsequent BMD studies on an individual patient should be performed on the same DXA instrument as the baseline study.",
"   </p>",
"   <p>",
"    Follow-up testing for individuals whose baseline bone mineral density shows osteoporosis (T-score &lt;-2.5) and for patients receiving osteoporosis treatment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of osteoporosis in men\", section on 'Monitoring the response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Risk factor screening",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of fracture risk in all adults is important (",
"      <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"       table 2",
"      </a>",
"      ). The principal BMD-independent risk factors to consider include advanced age, previous fragility fracture, glucocorticoids, risk of falls, smoking, alcohol, and family history of fracture. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Assessment of fracture risk'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"       \"Osteoporotic fracture risk assessment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     BMD screening",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest BMD assessment in all women 65 years of age and older (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Recommendations by expert groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest BMD assessment in postmenopausal women less than 65 years if one of the above risk factors is present (",
"      <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing routine BMD measurements in premenopausal women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H2#H2\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing routine BMD measurements in all men (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), but we do measure BMD in men who have clinical manifestations of low bone mass, such as radiographic osteopenia, history of low trauma fractures, and loss of more than 1.5 inches in height, as well as in those with risk factors for fracture, such as long-term glucocorticoid therapy, androgen deprivation therapy for prostate cancer, hypogonadism, primary hyperparathyroidism, hyperthyroidism, and intestinal disorders (",
"      <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"       \"Treatment of osteoporosis in men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For screening BMD, we suggest DXA over peripheral measurements (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If data demonstrating the ability of a peripheral measurement to successfully monitor response to therapy becomes available, screening with a peripheral measurement would be preferred due to cost, portability, and availability.",
"     </li>",
"     <li>",
"      For screening site of measurement, we suggest DXA of hip and spine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, measurement of the hip alone could be sufficient in older individuals. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Skeletal site to measure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repeat BMD measurements may be most valuable for individual patients on therapy or with underlying clinical factors that might lead to accelerated bone loss. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Repeat BMD measurements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women and men with low bone mass (T-score -2.00 to -2.49) at any site or who have risk factors for ongoing bone loss (eg, glucocorticoid use, hyperparathyroidism), we suggest follow-up measurements (approximately every two years), as long as the risk factor persists (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Repeat BMD measurements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women 65 years of age and older at baseline screening, with low bone mass (T-score -1.50 to -1.99) at any site, and with no risk factors for accelerated bone loss, we suggest a follow-up DXA in three to five years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In women 65 years of age and older with normal or slightly low bone mass (T-score -1.01 to -1.49) at baseline measurement and no risk factors for accelerated bone loss, we suggest a follow-up DXA in 10 to 15 years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A 65-year-old woman with a femoral neck BMD T-score of -1.01 to -1.49 and no clinical risk factors for fracture has a low FRAX-calculated (",
"      <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"       FRAX",
"      </a>",
"      ) 10-year absolute risk of hip fracture (approximately 0.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     After screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is only useful if there is appropriate evaluation and management of those found to be at high risk for fracture. Evaluation and management of women and men with low bone mass are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/1\">",
"      Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/2\">",
"      Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/3\">",
"      Rogmark C, Sernbo I, Johnell O, Nilsson JA. Incidence of hip fractures in Malm&ouml;, Sweden, 1992-1995. A trend-break. Acta Orthop Scand 1999; 70:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/4\">",
"      Jaglal SB, Weller I, Mamdani M, et al. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 2005; 20:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/5\">",
"      Kannus P, Niemi S, Parkkari J, et al. Nationwide decline in incidence of hip fracture. J Bone Miner Res 2006; 21:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/6\">",
"      Nymark T, Lauritsen JM, Ovesen O, et al. Decreasing incidence of hip fracture in the Funen County, Denmark. Acta Orthop 2006; 77:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/7\">",
"      Leslie WD, O'Donnell S, Jean S, et al. Trends in hip fracture rates in Canada. JAMA 2009; 302:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/8\">",
"      Johansson H, Oden A, Johnell O, et al. Optimization of BMD measurements to identify high risk groups for treatment--a test analysis. J Bone Miner Res 2004; 19:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/9\">",
"      Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/10\">",
"      Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004; 19:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/11\">",
"      Lydick E, Cook K, Turpin J, et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 1998; 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/12\">",
"      Cadarette SM, Jaglal SB, Kreiger N, et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ 2000; 162:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/13\">",
"      Cadarette SM, Jaglal SB, Murray TM, et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001; 286:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/14\">",
"      Mauck KF, Cuddihy MT, Atkinson EJ, Melton LJ 3rd. Use of clinical prediction rules in detecting osteoporosis in a population-based sample of postmenopausal women. Arch Intern Med 2005; 165:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/15\">",
"      Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/16\">",
"      Bettica P, Taylor AK, Talbot J, et al. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab 1996; 81:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/17\">",
"      Seibel MJ, Woitge H, Scheidt-Nave C, et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994; 9:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/18\">",
"      McLaren AM, Hordon LD, Bird HA, Robins SP. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis 1992; 51:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/19\">",
"      Seibel MJ, Cosman F, Shen V, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 8:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/20\">",
"      Christiansen C, Riis BJ, R&oslash;dbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987; 1:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/21\">",
"      Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991; 303:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/22\">",
"      Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med 2005; 353:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/23\">",
"      Nayak S, Olkin I, Liu H, et al. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med 2006; 144:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/24\">",
"      D&iacute;ez-P&eacute;rez A, Mar&iacute;n F, Vila J, et al. Evaluation of calcaneal quantitative ultrasound in a primary care setting as a screening tool for osteoporosis in postmenopausal women. J Clin Densitom 2003; 6:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/25\">",
"      Varney LF, Parker RA, Vincelette A, Greenspan SL. Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitom 1999; 2:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/26\">",
"      Mar&iacute;n F, L&oacute;pez-Bastida J, D&iacute;ez-P&eacute;rez A, et al. Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis. Calcif Tissue Int 2004; 74:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/27\">",
"      Bouxsein, M, Parker, RA, Greenspan, SL. Forearm bone mineral densitometry cannot be used to monitor improvements in hip and spine bone density after 2.5 years of alendronate therapy. Bone 1998; 23:S312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/28\">",
"      Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/29\">",
"      Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/30\">",
"      Blake GM, Fogelman I. Peripheral or central densitometry: does it matter which technique we use? J Clin Densitom 2001; 4:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/31\">",
"      Eastell, R, Wahner, HW, O'Fallon, WM, et al. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. J Clin Invest 1989; 83:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/32\">",
"      Melton, LJ III, Atkinson, EJ, O'Fallon, WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/33\">",
"      Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 1995; 98:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/34\">",
"      Davis JW, Ross PD, Wasnich RD. Evidence for both generalized and regional low bone mass among elderly women. J Bone Miner Res 1994; 9:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/35\">",
"      Kanis JA, Johnell O, Oden A, et al. The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int 2006; 17:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/36\">",
"      Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. file://www.nof.org/professionals/clinical-guidelines (Accessed on April 28, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/38\">",
"      Baim S, Binkley N, Bilezikian JP, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008; 11:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/39\">",
"      Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002; 288:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/40\">",
"      Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94:646.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aace.com/pub/pdf/guidelines/OsteoGuidelines2010.pdf (Accessed on January 10, 2011).",
"    </li>",
"    <li>",
"     file://www.uspreventiveservicestaskforce.org/uspstf10/osteoporosis/osteors.htm (Accessed on February 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/43\">",
"      Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/44\">",
"      U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011; 154:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/45\">",
"      Leslie WD, Schousboe JT. A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr Osteoporos Rep 2011; 9:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/46\">",
"      Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/47\">",
"      Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/48\">",
"      Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009; 62:105.",
"     </a>",
"    </li>",
"    <li>",
"     National Osteoporosis Guideline Group (NOGG). file://www.shef.ac.uk/NOGG/index.html (Accessed on June 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/50\">",
"      Rabar S, Lau R, O'Flynn N, et al. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012; 345:e3698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/51\">",
"      Barr RJ, Stewart A, Torgerson DJ, Reid DM. Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos Int 2010; 21:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/52\">",
"      Nelson HD, Haney EM, Dana T, et al. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2010; 153:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/53\">",
"      Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996; 11:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/54\">",
"      Yamada M, Ito M, Hayashi K, et al. Dual energy X-ray absorptiometry of the calcaneus: comparison with other techniques to assess bone density and value in predicting risk of spine fracture. AJR Am J Roentgenol 1994; 163:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/55\">",
"      Kelly TL, Slovik DM, Schoenfeld DA, Neer RM. Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine. J Clin Endocrinol Metab 1988; 67:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/56\">",
"      Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/57\">",
"      Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1991; 115:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/58\">",
"      Hui SL, Slemenda CW, Johnston CC Jr. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989; 111:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/59\">",
"      Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/60\">",
"      Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 1990; 263:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/61\">",
"      Greenspan SL, Myers ER, Maitland LA, et al. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA 1994; 271:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/62\">",
"      Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med 1992; 116:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/63\">",
"      Kanis JA, Seeman E, Johnell O, et al. The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporos Int 2005; 16:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/64\">",
"      Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 1996; 6:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/65\">",
"      Borgstr&ouml;m F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006; 17:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/66\">",
"      Johnell O, J&ouml;nsson B, J&ouml;nsson L, Black D. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/67\">",
"      Str&ouml;m O, Borgstr&ouml;m F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007; 18:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/68\">",
"      Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010; 152:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/69\">",
"      Kanis JA, Adams J, Borgstr&ouml;m F, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008; 42:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/70\">",
"      Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006; 166:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/71\">",
"      Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/72\">",
"      Leslie WD, Morin SN, Lix LM, Manitoba Bone Density Program. Rate of bone density change does not enhance fracture prediction in routine clinical practice. J Clin Endocrinol Metab 2012; 97:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/73\">",
"      Berger C, Langsetmo L, Joseph L, et al. Association between change in BMD and fragility fracture in women and men. J Bone Miner Res 2009; 24:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/74\">",
"      Nguyen TV, Center JR, Eisman JA. Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res 2005; 20:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/75\">",
"      Ahmed LA, Emaus N, Berntsen GK, et al. Bone loss and the risk of non-vertebral fractures in women and men: the Troms&oslash; study. Osteoporos Int 2010; 21:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/28/40393/abstract/76\">",
"      Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012; 366:225.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2046 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40393=[""].join("\n");
var outline_f39_28_40393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSESSMENT OF FRACTURE RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factor screening instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Biochemical markers of bone remodeling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BONE DENSITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Quantitative computerized tomography (QCT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Peripheral measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Skeletal site to measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Candidates for BMD testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Recommendations by expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFECTIVENESS OF EARLY DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Arguments supporting screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Arguments against screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FOLLOW-UP TO SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Repeat BMD measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Risk factor screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      BMD screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      After screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2046\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2046|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/59/9150\" title=\"figure 1\">",
"      BMD bone markers and hip fx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2046|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/28/11723\" title=\"table 1\">",
"      Osteopenia and osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/21/2395\" title=\"table 2\">",
"      Risk factors for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/52/846\" title=\"table 3\">",
"      Osteoporosis screening recs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_28_40394="Junctional EB Herlitz 1";
var content_f39_28_40394=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86264%7EDERM%2F86267%7EDERM%2F86269%7EDERM%2F86270%7EDERM%2F86271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86264%7EDERM%2F86267%7EDERM%2F86269%7EDERM%2F86270%7EDERM%2F86271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa type Herlitz (JEB-H)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized blistering, crusted erosions, and extensive areas of denudation in JEB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa type Herlitz (JEB-H)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized blistering, crusted erosions, and extensive areas of denudation in JEB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa type Herlitz (JEB-H)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blisters, crusted erosions, and large denuded areas in junctional EB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa type Herlitz (JEB-H)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive areas of denudation in junctional EB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa (JEB) Herlitz",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 471px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nail erosions with periungual granulomatous tissue and incipient onycholysis in JEB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40394=[""].join("\n");
var outline_f39_28_40394=null;
var title_f39_28_40395="JCAHO protocol for surgical timeout";
var content_f39_28_40395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    JCAHO protocol for surgical timeout",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       1. Perform a preoperative verification process (ideally with the patient awake, aware and involved)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ensure that all relevant documents and studies are available prior to the start of the procedure. Identify the patient with at least two patient identifiers (eg, name, number, telephone number).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ensure that this information has been reviewed and is internally consistent as well as consistent with the patient's expectations and with the surgical team's understanding of the intended patient, procedure, site and, as applicable, any implants.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Missing information or discrepancies must be addressed before starting surgery.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       2. Mark the operative site to unambiguously identify the intended procedure site",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       For procedures involving right/left distinction, multiple structures (such as fingers and toes), or multiple levels (as in spinal procedures), the intended site must be marked. Ideally the surgeon in charge will mark the site. A procedure must be defined for patients who refuse site marking.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The mark must be unambiguous (eg, use initials or \"YES\" or a line representing the planned incision; \"X\" may be ambiguous). The mark must be visible after the patient has been prepped and draped (eg, use a permanent marker). Nonoperative sites should not be marked.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       3. The entire operating team takes a \"time out\" immediately before starting the procedure to conduct a final verification of the correct patient, procedure, site and, as applicable, implants.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The procedure is not started until any questions or concerns are resolved and all members of the surgical/procedure team are in agreement. Identify the patient with at least two patient identifiers.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) at www.jcaho.org/index.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40395=[""].join("\n");
var outline_f39_28_40395=null;
var title_f39_28_40396="NAC established therapies";
var content_f39_28_40396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Autism Center's Standards Report summary of established* behavioral interventions used in education for children with autism spectrum disorders (ASD)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antecedent package",
"       </td>",
"       <td>",
"        Interventions that involve changing triggers (antecedents) that usually come before an identified target behavior to increase positive behavior and decrease negative behavior. This includes treatments in the fields of applied behavior analysis (ABA), behavioral psychology, and positive behavior supports.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavioral package",
"       </td>",
"       <td>",
"        Interventions that use the principles of behavior modification to encourage functional behaviors and skills as replacement for negative ones. These include treatments in the fields of ABA, behavioral psychology, and positive behavior support.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comprehensive behavioral treatment for young children",
"       </td>",
"       <td>",
"        Interventions involve a combination of ABA procedures delivered to young children with a low student-to-teacher ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint attention intervention",
"       </td>",
"       <td>",
"        Interventions teach the child to respond to the nonverbal social bids of others or to initiate joint attention interactions (eg, pointing, showing, following eye gaze)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Modeling",
"       </td>",
"       <td>",
"        Interventions involve imitation of target behaviors that are demonstrated by an adult or peer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naturalistic teaching strategies",
"       </td>",
"       <td>",
"        Interventions use child-directed interactions to teach functional skills in the natural environment; interventions provide a stimulating environment, model how to play, encourage conversation, provide choices, and directly or naturally reinforce and reward reasonable attempts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peer training package",
"       </td>",
"       <td>",
"        Siblings or classmates without disabilities are taught strategies for facilitating play and social interactions with children with autism spectrum disorders (ASD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pivotal response treatment",
"       </td>",
"       <td>",
"        Targets pivotal behavior areas (eg, motivation to engage in social communication, self-initiation, self-management); parent involvement and intervention in the natural environment are key aspects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schedules",
"       </td>",
"       <td>",
"        Present a task list that communicates a series of activities or steps required to complete a specific activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-management",
"       </td>",
"       <td>",
"        Teaches individuals with ASD to regulate their behavior by recording the occurrence/nonoccurrence of the target behavior, and securing reinforcement for doing so",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Story-based intervention package",
"       </td>",
"       <td>",
"        Involves a written description of the situation under which specific behaviors are expected to occur; stories may be supplemented with additional components (eg, prompting, reinforcement, discussion, etc). This includes social stories.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Established treatments are those for which there is evidence of benefit from several well-controlled studies.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The National Autism Center's National Standards Report. National Autism Center, Randolph, MA, 2009. Available at: www.nationalautismcenter.org/pdf/NAC%20Standards%20Report.pdf. Accessed on May 18, 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40396=[""].join("\n");
var outline_f39_28_40396=null;
var title_f39_28_40397="BNP levels etiology dyspnea";
var content_f39_28_40397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma BNP in the diagnosis of dyspnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 331px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are the plasma B-type natriuretic peptide (BNP) concentrations in patients presenting with acute dyspnea who are diagnosed noncardiac causes without or with a history of left ventricular (LV) dysfunction, or heart failure (HF). Patients with a diagnosis of HF have significantly higher median values of plasma BNP compared to those without heart failure (675 versus 110 pg/mL). The boxes show the interquarile ranges, and the I bars represent the highest and lowest values.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Maisel AS, Krishnaswamy P, Nowak RM, et al. N Engl J Med 2002; 347:161.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40397=[""].join("\n");
var outline_f39_28_40397=null;
var title_f39_28_40398="Ig heavy chain gene rearrangement";
var content_f39_28_40398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Ig heavy chain gene rearrangement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 327px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bona, C, Bonilla, FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright &copy; 1996 Overseas Publishers Association, N.V. Permission granted by Gordon and Breach Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40398=[""].join("\n");
var outline_f39_28_40398=null;
var title_f39_28_40399="Hysterosalpingogram a";
var content_f39_28_40399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 329px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFJAfADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxUDAJ/wDrU9XJxxVZnKv7U7zQFzSOVpltXDcEdKTBGTUKEHkHrUwJ9aLCGkZ5JzTTxnb3qQrk0wrjHrQFxquQMHk1JbyqxYIykqcEDsarXMTyQOiOUdlxuFcvZ3M2lag4lz1xIvr70yox5kd0Hwc09ZAe1VIHFxEsiMGVhuBFWFOABQjN6E4ZiuBVmPO3JquqlfmHNTRsxzTAnUhsKODTXjbdu5NNWPjfnBqa2Y78NQBdtGIIBxXQaaArBzWCiZIKda2oGCQ45BppEs1Jiz4YH5RTFk6iqsc/TGcelTZ43Y60WEWEXeAGPbuaZNEOOAT3qMy7V+9U0cgPU5zRYChKoOeOnamQ538Cr8kSk5FRsioPl5P8qdgIi4HytjNRELvwB83an+SxYvninIiK4ZutKwDWjZQSwzmmSZxhRxVpn3r1HFQbuSQM07AVpotwwQAKpvabCT1FbIUNEQRk1XePsc4osBhTxlTx+NV/LyflrVmjByDjGahWEI3XrSsFym1uuz5utV2tyX46CtiaIEBhyaakHIycCiwXMaW17v0qxZogbCDFaciRn5GA4qNEUZ2iiw7kyAA5x0FIpLsc9aadygHHAp6OqgFutFhEyZHt6U85br/+qo1cs/8As5qyuQeRxigCW2RjIA3PtWmtuduQOaisMEjdxV0uqNjP5UwM+6TAwFAYVSlLkEY4q9cFmkyTxVSV8NgcClYDldYbEhDDmsgzEDaTk1ta9Gdxf+Vc27EP70mWi4ZsIOcCiKXnJzUCRlsbql8klhjOPakNlwEunH86XGFpsEDryelWimcBaLBcruQ+PUVXaLOSenpWgIlA5XmoZ2wQABTC7KbrtOcYpu4MeM1PJEWX61DsMbDnmlYB2ck8cUjgAfWnjJ6ZzTnjDLx+tAXIU5PTn1qVEbGaYsbDkVMmQvzZ5oSAeigH5qXCscCoyG9afHkHJAosAbT3Fa2jD98uR36Vlknf3/CtvR1+dTgnJoBs9M8L5+Q/lXp2knMY+leY+GBny84+lem6UCIl700YSep8Ryr3ojj3jIGakcckH1qSJmRWC5wRg1KOkiGBwKnjYEYINQ4+apl46daBMeCBxQ5ycDFKQAmTUak7uM0xDyMj3rI1zSzcw+bGv79Rx/tD0rZQbxnOKkCgjGaENScXocj4c1E2s/2ac4ic4BP8B/wrsVTBBzXL+KNJ2ZvIBweZFA/WrXhjWPPRbS4f94owjH+Ien1plzXMuZHSjOAKkB5waSPDrxmnCPHrmgxFLF2A6AVPGhDA4pIYsn7taNpbszgMOKaC5a02LKhmzWg7KrYBzT4oRGg4xVaXAlyOc0yR8YLvkHAFWd21QPSquNnzA0+J92epoAkB3cdqkAOMjNCMFXoKcHLdOKAuOMhKAAmkiYAbSeppWACZPBqucEfL+NAGg21EHT6VUkTe2T0ojkAGWOT71DLMxk46UAWVGwZwDUJz1XjJp6EvFjNIob5QBzQBNaxnPJ61LNAQhY/pU9tHjbn+VS3IwuKBHNTKCTwapucsAex61ozJtkOfWqlwmCTigYiqcjnqasSQAYI6mo1jPysOlTojcZOaBFR4ju+tO2Ko4GPap5cq6nFNkLOwyOv6UDK/JlIOPao50zIBg8VYNud2QferGyMJu6sO1ADYkG1Se1Plcbc5/KqskpAznjPIFRIxYk5+UUAjWW82qoX86sRSFxknmseOTdgCpy7RpnPNAGjJIoG0nJ9azb6Q87c8VPCdwy3U1DeIcEdR60AZEv8ApERB+9WPcaeRIWxW5d3EGmWz3V2xSBcbiFJxn6Vm6Xq9prjXJsjJiAjcWXGc56c+3ekWk9yskWEyRnHFWIoj1xx2xUs0YHA/GlgyAATx70mgJ4cEbT0FNb5MnpUuBG24nk0s5DqCvNMRUZwWJNRMBJnjFSONuRjrUXWkMaEyxCnpTZFGe2KXBU8U8ZPFAEOcc45pwPGTT9p5wBimHn5QKQDo2U8YqQQM/QjHao1jIG49KsRyMowOvamAxbZg2TUckR39D+FXo9ztknBqyI1K4x+Ip2C5mQxHGTmtrSSyEYB6dzVQjBwBwDitCyOJF2jv160CueheGUdSjAA5969P0z7g7V5v4YDFI84JNekaUG8obutCMpbnxdcgLMc00Ae9Xru1bZvqsqjAqTdsiwM8VKqjjPWl8vBPpT1TimK41+F5piHnkVK4H8VIQGI5oAVSBnFOQ9D6UscfrT2AUYphcY2DkMAQeMetcXrumyaXdrPASIWbcjD+E+ldsqh+vWnS2cN5A9tOMo4/I+opMqE+Vlbw1qa6na9VFwgAkHr7/St6GPeNx6V5i6XfhvWQVzhTwR0kSuts/FMF3qNrbWq/LL98vxg+g9TQmVOHVHURphgBWxY4A3HB9KyoGDEA9elbdrCPLUjtVGLJ5z8mB3rNcMDgHrVq5kO7av51UfO6gQwsQduc1NatycZqu8ZAyRViAYHy9TQBoAA4JOKeBtJIHNU8NgbjzVqMkpknmgBZGAHJzVVMs5CjFPcZxjrmnImASDg0AyBwwIxzSbvlwRU7Al/akkjBAwaAESQLjaealhYtMDz71XjiUPk1agAKnBoA1EuFyB04qS62mHjrWZb4Mq/XArRuAAgx06ZoEYt0VAz71TIZm+Y8Gr11EAeBwagEZJx6UDHRIcLt6e9S7AM1G4aMqM8UjOwfgigBsuQMGokfk+xqU4cHJ5qPATOehoAQSZJHrSYw/wBaHy2No5FL5ZOCetAEZjBByeDS+WoJxjAqTBUHPJpAmcY4x1oAaq4f7uPSpWU96dsZiD0xU5UcZOTQBHESSMgbanCZbbxTY48npxT0zuxxn1oGYviuyNxol7CnV4mxn1ArzP4bXJi1S6g/57Q5/I//AFzXrt848t4zzkEfnXifht/sHjCOMcKJXhOfTkf4UmbU9YtHpEh2SHd0xSOCQGU8VPPFuXd61DuwMEUGdyYb2TnmpIkZBz97tTYD2YirL4BoEytIu4knG70qJ4CFyAB3xVls79xAzST5OMZoBMqRxhjyBTtg38DpUqqV96lEZIz2FAXKrRn04PpUEkJTkVqRqDjPFEkKs3B4oC5kLuPJNTRDbyfzq00canApFCkYwKB3AEsox3qWOXBCk/lTNu3H8hT0X5u2aBExTDhj0q/pqneMDAzVePDrgjNaNgv7wAcfSgR3/hrBEY7V6PpwwgBx0rzzwuqhkGDXodjnigykz5IuAGRl/Ssll2kjHetcAPJz0NUb+ErJwODSsbXK/B+lO5IH6UoXavSjkY4pgQMpapFj5GKkWPgk8CjYccHigLiYI4zRt44YnNKcketSIoziiwEYO0dsipI+eW/TvV23095VLKvHvSPZsAQSOOKLBc4jxncXM2yN7XZbociUjOT9e1c/pk5t9Qt5VONsgPXHf1r1cWuU2cMp6gjINYOo+E7a5YvbZtZRzlRlc/Tt+FKxvCqrWZ1SOojBA+b+VaEFyVh5JzWVYwyraRCbaZFUBtvK5Hp7VoWkBlYcYqkc7HmRic560+OQEYByauvpshjwqkmn2+kSqM7T9AKaRNzOkJOMtgelTQt+Zq7JpE7kny2x9KiezlQhdjDHtRYY0dOTmrEe0D5TzULW8ykDaR+FT29vIo5U9euKLMLjwmRwOacISOe1W4oDg8Emnm3d1zsbFFhXM9sA4qEbi2RjFaKWMz5xCx/Cmvp9wqnEDj8KLBczztUkZyTT4Tx1xUkllMg3GJh9RSeS4wNpGaLDL1hFulBIyK0LyH5OOlGl2zJEXbuOKlJLxyKDzSJOemGHO4/Sq6th93arUkZVyW57c1CI+eBx6UDI2bLYbBHamTYwMDnvU6xtu5APNNnTL0AV4iFyScZpSpZsjFL5YwafbgFsCmAixgIMZyKnCEYzjHpTghD4PSp0TzAMmgZUdBmneSoUGpni6cUScKBjmkBGpC4DU9mA6AAdaZncVFJyTg0AEzFVzzjrkVC0mDkHkVLcSYQDAqhcOQuRQMgurjc/zCvIfEg+xeL5ZANqiZZQfyNerSyB8eorzb4iwlNWgm7SxAY+h/8Ar0ma0d7HoqSfu1zjbjP1qORVZgyniqGmXJutGtJTjLRL+eKkjZ1ODytK5LWti4cIQd1SLMH69qqSqWjDUxCQA2elFxWNdCHX5h0qJ84yRUcMu7gngVaBLYxjnuaYmQg5XtQHI5p5XLHP6U11CkA8n2oESKwKHPFMkB4wRUTEMepFSr8xwPyoGVJvlao9+c4wD0q7PEM84qmygNjFA0KhOdpJzViNdpznIqvEPmI71ZjQ4ByKBMtQ5P3eBWrpA/e8/SsqA8jFbWmYWUY65oEz0Pw2AAufwxXfaccgVwHh4AIGzzXeaWQUX6UGMtz5ORSWFS30G+MEDpUsAGT7VZKh4yvHIoNm9TB8vnApjptPNS3BaOQrxwaj+9k55oBDf5dKHXB+X8aRjwaTJwe9ACAY49akT5Tk9aApx2NIu0tg8UAdBaTYtMgY4rJnkLyHBPWr0KEWp5OMVQULuP1oAlgfYhJPNPVieSeDUckZ8sN2pyt+7x6UDLtou5hg8V0FnbqWXZ19a5i3l2kHNdHokxkuFFUiWdtpGn+ag3DiumsdFTILKCPpTPD0YaJciurtowFGAKrYxbdyhBo0BXBjH5VP/wAI9ZufmhX8q2okGAanVRipbEkc/wD8IxYMQWgU/hTx4W07HEC10CgU8AUrsdjnx4ZsAeIF/Kpk0GyUACBMfStrFOCii4GMNGtl+7EgH0p50m2xzEn5VrECgKKLhYw5NDs5BhoUP4VSm8J6fIwJgUV1W3ikK+1F2Fjk38K2hXaq4HtVGTwZAA2xiMiu7KDHTmm7OcU+ZgeW3/gSRifKk496yJ/A1+mSgBzXtPlDNNMIPYUcw7tHhEnhXUYiS0LH6VnXWlXcbDzIGAHtX0K1uhPIGPpVebTYJMb41P1FHMh8zPneW0ZSQyED6VEkGw9Ole+3XhuxnHzwpz7VjXfgWylJMeUNGg1I8kWIbc459acgVM4xXolx4CYf6p8/Wsi78F3kSsVXcPanYFJHGySYz+lV3fIyRya1b7SLq2crJC459KzZYm3hdpB+lJopNEKjD5JoY7XODmrXkFSc+lVDG27JBxmkNDJTlenJqhcEE4yTWg4AHToKqvGp6CgZlyEJ1HFcT8R4Q1paTjqrlPwIz/Su7u49vXrXK+M4RN4fn2gZjIcfQH/DNJmlPSQ7wQ5n8NxHcCYmZMHtzn+tayrubjrXI+AdTtbSwvYbu4ihy4dd7AZ47fkK7vTljmjjnRg0TgMreoPSgdRWZLFakQhn/KqN1CynK9K1ruQkYB4A4qh5m8FT1oZmirAGRgTnBrRjYcZNUlcxybdvFTwbmcYHWkDLJIyeeKgkYkipWhbknNMVDu5H0piK4B3Fjn6VatTub0NK9uTgjpToojGQT1osNi3CYXJNUicnIBrRkwVw3SoPLBYBelAivgZyB71Oq5I4pfJVT1zUgxjofagCeBc/NitfTh+9DYPWs61U7RW1py9CR+VMTO10MEKnueld5pAJRcelcDosh+Xmu90k/u1zSM5HzBAoTngkd6eWwxIxVfoxwakAJHUCmaMpahEPNJOORVQR4IrTvo8x7+4FZxyTyOKQ0MdAF4pioRycGpfLYnIOBTH3LQgGknBFKqcgmmnBNKuW6UAaTTf6OFFQQxsz8cVECQMAdKvWynYWIwaALEkAeLbnpVIw9iTirJYlqteWjqF/iNMWxnqgUcGtjSJvInR89DVOW18sZHzGmQqwcAnk0ID2/wAL3YmgV1rsrRwyivHfCerNaqsbk4r03SL9Jo1Icc1RlJWOmiPFTqeKpQOMAgirkZGKliRMtOFNWnZpDFIpyikHPFOFAhe/NH1pcZ5pcCgBMcUY5pRS0ANxQBTqDQAhFJinDFFAxuBRjNPxxSUCGFRRs4p+KWgCIxg0xogeMfpU+OaCOaAZm3GnW82RJGpH0rCvvCNhOxbyQreorriKYy07sZ5fq/gt1Ba1IOO1cPqOlXdpIUlhYY7gV9BPED1qnd6fBOMSRq31FO402j55eBtvzIR6jFRG3DdBivbL/wAM2kgOIwM+lYN54WhjyY1H5UWHznlF7prS/dGDXl3xI0K9sMXqTTyWchCyR7iVjbsfof5/WvoPVdGaIMyjFcfqunpcxS21yN0UoKsCOopNGtKdnc+d9KtWv9StrVQx82RU+XqATzXt0w8kLGowiKFXA4GO1cf4Z8MyaT4wufOXdbwITDIR97d0/HAYH3+tdrdnBG05yaSNasrvQrF8rjPNV1Qhs9qurEpXccA+lEkZ2jGKDK4hhWSIFR8w65pIlKNnpSxFlI65qSdCqbkz6mgCVZNwyRSSHkZFUhKQcHOfSpPMLjOQMUBYsSEqvy01WDjJ65qq8rH5QasRR5jyCM96AJ9obqaYVABKcmlMeQBnmhU2mgQwISeRz61JDGSxyeKtBeAc/NT40BYqFO4Dr60AOtQM4ratgFQYNZ1tHgcir0O7zRn7tMTOt0LBVcmu+0kYQCvPtEU7hjgV6DpJzGuKRnI+Wt4DE4JNI1wRwQBUUrYPBph6ZNCNmK8rP8rH5aGQYzUPO7IzVhJOxoENCjueKiYDdz+VWHxnpjNRSR5wc8UAVZV+XK9KbFt6HrUrruBGTgVEi/PkUDLsCKzAc1bZgFCqOKfaQqIt2OaTy8vjH0pk3EjHarUeFOcZalhi2r8350ryLGeMUAP8zByQeat2qRO2WT8aymuAGySMelK2p7V2pQFjeLKmPLOD2rX0PVp7eZRv49M1wZ1GT1zUsGrMpGOoouDR9FaLqQmRMtz3rpIJQwBrwnwn4lKyKjt9Oa9X0nU1mRcNnIqjGSsdUjd6lBrPhnDKDmrUb5+lSwWpPyaf2FRK3pUgPHNIB4peKQGlFACilpB0pe1ACHApRQelGOKAClAo/GloAT6UuKBiigBKUdaMUUAAFHH40c5ooAQ00inGmtQAxuaYw44p9NbpQMryAEVnXaDB9K0ZjWbeSAIaaEzmdVhjYENjpXn2v2CPJuRsEV1nia9+yxPITz2FeYalrU807YbgdqbLgitfadNGDht3pWLOk0Zw2SPWtV9TmJ5pkk6TptcBc9M0jRGK9yc7Q3P1oNy4AJY4HSnXVmVbcq/JnrVV4yFYMc4/WpKVi/a6ghcbiK3LYx3CYBHI4zXESZTkjHNWrHUJIWAPajYGjoru0MbZwcH0qmW2MRWpYXiXsW2TqelV7qxYSHaDg1ROxSwDliOT0xVyFTtBPSkWLZgMOasKMHA6UguPRB0Yn2pwA3Y9KQddxp8YznPemIajHd14HarcDZHHTrVQpnp61cs4iSeOlAy5Fg+1T27ZYA9M02OI7eKs20Q3YPBoJZ0ejZ3KBiu/0YHyxnrXBaKu10AyRXe6UeFz1oIkfKToN3Xih/QVJIq4OOtMCZGfSkjVsRBzyKkVOcmnIh29OKkiQ9eoosAjrlQMc1A2e45q4eaiJz/DzTsCKbjA706zh3yjcOKm8hnfGODWhFbCGDphjQJsFDElRwBT2VI03Eiqk1yIFyGyRWbcXryDrgUBYvXN9j5VPNUjcOx56GqqsGOSeKVnB4pDsTlwVIzUTtjvxUIJ5pcAHmgaAS89akR88moSoJ4xxSqp3elMDTsrtoXDKelekeEfEUm9VJJryxQdpya2tBu2tJM9V600yZK59GafqiyRryOlbcV0u0fNXhWneJZBwDjFa0fi+4AG3ntQ2ZcjPZ4rpW71aSUNjB4rxtfGkkSjj5q3tF8bRSlRN8p9aAs0emq1PHIrH07U4buMNHID+Nacb56UmInFLUamnikA6kH6UoGeaXFACDilFGKKAFFJilAooAKD0opaAG0GlNNNACH0phpze9RSMB3oACcdKax96hlmVBkkADvWVd6zbRZBmXP1oGXbmUKDzXPatqcUEbFmGRVXVPENvHEzmUcDpmvJ/E/iOa7ncIxC9KYKNxfGevPd3DRx/dB5rkC5yWOPxouJWdyWPNRcvjNBulYlb51BU801lHBbqKlUhUGaHG4e1ICS3ZZEZGIIxVV0/fkbRimq3lvjGBU6uD2oApXFqjtxVGW3w2ADgVuYA6jNNnjVhnHagEzMgkeBgVJGK6bS9QS4j2Tk59awGUNwoFSRAq2F4xQD1OiuIE3DbyeuaQW5VMDjFV7K9DYjcZI71qv88YPf2piKO3AwcYoQkkjb0pXQ7W9PWmRo2fkPFAiZQpwDwau26bRjJNVlABB4zVu0ZQ2OTQMuQR5XirEa/MMdabyF+Xqakg3BwMc0yTodCyGG7rXeaVyoz1ridIPK5xXbaX91fekZs+XJkVZABQEAJ96smME7u9NWP5vU0ka3IUQnoTipY0IYelXREAvSiKIMct2piKzW+SKctvx0FWWIxgdR3qSFTvDE/KOtNBcS3s1RPNkGAKyNXvgGKRGrutX/AMoji4WuakOSd3XNSxpEZdnY7ulI49uKHGD3pqtng9KBijkYxxS45pRgcc05VPUUDFC8cimsjE47VIH5HegkHgZzQBCUZcepp4BYqOKB3Oc0sYLH0oANr7vlNaUHyRru6mqtsmJPm5xV1mGRgA0xFqBtoyDzV2KRl5DVnxJk5Iq0idMnGKCS4Hz1/OpIZWHfGKphiGPP4VJGxLcnj6UwOp0fXbmwkVo5Gx6V6V4d8YwXKJHcNtkPBya8at2UH5qswTEOTGeR0oE4pn0la3CTIGVgQatKa8e8I+K3tZFguXJTOOa9XsLuO5gV42BBGaViLWLop1MU08HNIQopO9L9aT+KgBaKWkoAKMUUUAIajZqdIeKoXNwE6mgCS4nVFJz0rk9a8UQWhK7ssOwqPxJrSwQFVbkjFeWajcNNMzEkk+tUNK5va34rubqN1iYqO2DXDXGp3DykySuT9amklIOM8VRnQFvWkaJILi7lkGGZiO9ZsxJbHWreGBwP1qtKpzk9aCkVcZbJpd2FIxTgDv6USJkZJIpDGgMck0b+pNIQVGB+tKEyvOM0AJKoZcr1pkanPfNT4CjpSMO/ftQA5X2kZpZDwP51WcfMPSnO2AADxQFhSMscCoi5UnjIqeNuOelRkdQMEZoAIGbcSOvat62uCsID8gjGKwI8K2ecVpW579R6UITNGQ4QHsabHhGJX7pqKObJxjj0qZABzmmBPtzhh0qaL5Dx2poIAHalQjIzigRpWzEjk5FWYiQ2cZqlbkqR6VZhJL5PSmSdNpR4HrXc6Sf3a5rgtKbDggZ5ru9LOVU0iJHzksPJ3HilEZP3QOKtOmfujAz1piqwOBzQjRkQJPHcVJEh5z3qwiAL/tUjABqYETIq9hWfqF00aFE71bupAucHmsi4/eZ3E5zSBFR3J681VYe/JqzNGy460xUA60ikVGyTyOlM2jBqw6DeSKbIuSOgoGRoCRgjmnR5yaQHDdacASKAHRrzSkHt1pBwMd6dkr060ACqRxjk0sSHmp4V3gHuPWphECcDGaAEto1QMx5NSxgM2RxTzEykLUixgHjFMlskTHHPNSYJHrTFUEcVLHgHBOTQIVThiGA6Vatgp96qOuSSOfardoMLkigCU8Hkdasx/KOBUagO1TBQM45oAdE7eYDk8HtXp3w71llb7NI2R2ya8xgIVj1zW94auxbX8bE4wcVSJkj32JgwB9amWsvS7gTW8bA5yK0VNTsQSijvSA0tIBaSiigQtIaOlITQMZKflNefeKdWNvJIA3TsK7u4YhD6V4z42nP9pSrnoaaGtWZGqajJcsQ7HGcist2ySaewBGW4NR/xYHSg0RWmj3fMRxUEkII9+1XZTwM8U1F67iBnpQNGRMhUkenWonAI5/OtC6iIGRg5rPmGBzxQCIXUbulJNjA4qTII+Xgio2XJzmkMrSnnoaQEhgccVLJHuIyeahkk8ocnIoGTvkgYOPXA60JkjkVHFKGB5BB6Cpd3AweT60CGyIu04quV+cCrSDAOTTSu5sgc0xkBUjIByKAeOR0qwg3ZyOlBjzwMUgIo8FxxxV2D7vHFQKpAI44qWMHbgYoEW4V3Zz371KCI+vNVPMIGB2p8b5GW5zTEaCOHp57Y7VUjJV+OlTrJlht6UwLsMjjAJyKvwPxnqBWSJPwPpV2zc/hSEdXo7jAyMV3ekYIXGcYrzrR3DSDPFehaM3yKDQZyPDGQnOOlQ7CG6Va3A5AqN16Fc00aMZuwCDUEj8kjrTpCRVaaTb7CkBBctv5PWqxjy3BqUnPLHIzTSdpPpigCrPnHPaqTZ55q9Mwbgg4qq4UNx09KBorscDrTDg9c1YkUDtUQUA8jNIYzb0PenD5SOlKCM8jmmy85wKBi8HpjNKqHAyaZCCOtW0Q4GOtADoAQ2McVo21uWcMy/lVe1iLSjPStXescQVfvUxNle6XJAHQVCy4xzzUrOT94/lSBSTkc0CGjd1yADUsQHU4psabm+bp9anCKDkdfagQIvPTrVmM4GKiJIYYPNTJnPOKAJAQcbePWpOVYVGAFPTipGbI4oAnBzyo61Zs8o4I42nNVYDleBzViAkOQTiqBnsHgzUvPtUQt0rso3yM15B4Nu2S52gnmvUrGXcgz6UmjLqaQIp+eKhU8VIDmpAcBS03tS0AL2pppSeKYaARVvW2xNXifi079UlyeM17ZeDMRrxbxchTVZAwwM1SHHc5wg4weaQ5HA60r53UjjuTQaEcwz1IqJSykE8/Wp3AIBqvKcnGCPekMezB85HFZ91DnPUDrU5lC8VJlJlwDj3oAyihUnimOPxq7JFg96h8vOe3p70AU5RkALkH1rPvYznPOa2QmAM4xVe9TMRPFIaZz63BjfBPy5q5HdBmHPFZt1gEgVS89omxnNK9i7XOoEwbpU6kY5JrCtLkEgZ981swbWjBBzTWpLVieNBnPUVIyADLZFEXTaDzUrENhfzNMRWcAY561LxtyO/pSSr93mpQoCAd6BMiPt+dSwKp45J9aNq4wOppWPlDAHzUASktG3PIPSpUOfb6VXDB/vA4oVju4GBQBdX5fmzk+hq3A+OlZySD1q5bkE8HFAjpdFfLLnr616LopLKh9K820QEEHqK9G0N8qoHSgiR4s7AE015RjA61HOrBieo71GjjPJFNFsbIWAbPNUHJYnd61ozEdhVRwCcjr2pAVnQAjFNdQw44NTS5wCVxTcDPHWgCsVGSCOahKDcRirroGOcnPtUDRjdnmgaKM5AbAFNA3J05qWWM7uT0oj+VwOxpDIjF8vNMaM9eKvshzUTpntQMrRKc81oW8Qzn09ahjUL96ntNhccUxGikkaLgD5qaxXIIPJFUYiGPzGrHAxzmgGiRl4BJ4p654I7UKuY6lgC/MO9BIu0AcDrSp19qXbziplXC4wKAIhyw3Dip4hu6HpTAhP4VIoxyBQBIVIHFTRKCo6c01EbHJyKdGMMQelAyYEIABirEZ4ywwapE/PViPJAJPGaBG9os5guEZema9a0abzLeNu5FeO2Yw6EV6f4alY28YPQCq6GcjrYz0qYGqsR4FTqeKkRLnijNNzRmkFh1IxNNJpCeM0AQznivLvH9oBOHGOa9QmORXA+PUBjBxzmqQJ6nmhAVvn5J9KY5UggZ471dmj+QnAx2NU0zyCuRTNERZGOc8VVnYYOG5qxNnGAByapSgA5xzmpKKznJwzcUxZdv3c5p8oJOKYVAzgUATxTlxh+tSFQxOO1VYxuGfSrCS9AT7UARugzVe4G5CpHXpWhLA23IBqlMhyfagDlr5NrsOMVj3H3q3tRXDHH41hXJG4gUmaxY2GQxvkVv6ZdA/eOPaucXg5NT2lwUlBqbg1c7aFhjjqalGCwxWXY3AdF5BNXg5xmrRm0TADcSelJ5gGSeTVdpMDk5/Gqs84D5PFAWLzXCJycY7VA1x5r55zWZJP5hHpT4pcAHHNFwsbETluvaraR7hx0NZtuTtHI5960rNuPm64oEwVQOMdKuW/wB4Ed+1QKuX4HWrUEZEn0oA6jREPy54BrutFfy4xg8niuI0eQFl45rsdNO509B2oM5HlFzsyyr3NVGtwFyOT1rSvbfDlgM571HsGyhFFBk7EVWYANyOlXrgcHHGKruQVGRxTGQSfMAOCKhKAdVqaTBWoWJHynmkBGAc8Y4oYZQ8c0/GDn1okIXtz60AUWVQM4781UnwCGGeK0ymRz+NRSRdcDpRYdyKAmRATkcVYSA/eY/LTrGFiTuBAqzc4+z7BxQBjzOC+VPGe1RAHrUvlEA8cA04LnpSKTEjIHYVbhTeeuKgROenA61ftyoXpzTE2SxRnaeeKds2jgVJEQOCDzVhVUqRQIgAJAxmpyoKgY5pyJgdKGHBxQAmwgEA8VKifLxTU5AzipRyfp0oAbjGBzxTwuO/NKw43d6GIxk0AMdPmGOlTw5Zh7UxMVoaZFvuE474xTQmbWh2JmALDoa9E0S18lR16VV0fTEWGNtoGRzXRRRBAAOgoMm7lmLgCplao4xnrUgGKQIkzRnAqMkikzkUgJc00nimZ4p3Y0AQyng1wfjlsovcV2102wda4jxmd1rlumapB1OFlIORgbagdB1zjNPBYHA6U+WPCDHIpmhmTxsMnrVCT5c5HNa0mOc8elZ1yvoMgUhoz2J3EHk1GMnJqSYAdveo8gHgfWkMeBhDzzSwpmTPbrTMhiQO/FW4YvLjG7rQBOkpxhuRUVzECpZM5NN85FAGRgDmkW5jB5NAHLashEjEjFc3dZEh9K7XU5oJWKtgH1rl9QtkHMbhs0mXFmVnJxzSF8NSujjPTHtUT8DGKk0Wpq6Ze7GCu3Ga6FLoNHw1cTE+1sirsN4yj3p3JcTo5psYJaqE0vmkjOBWeblnPJp6TEnB/KncVmi9H2Gc4q3EemAMVShkDNgcGrAcg/LjrQiWX4iw7itC1dsg/pWZCcEM3Q1etjyAD1piZsqT1xVmDOetV7MtsAIBFW1yik460IRsaVN8+wE5zXb6RKEAOea4HRSDIzFfmBrqrG4LSIAeBQZyOYilSWPaxGe1VZx5YZfWs9WZGOeAPWpZLpWT3plWGTOpUkiqcrA4FOeXOSD+FV5iSeDSGPxkYHFQyRHOc07cVABpVY46ZoAYiYODn3qKUHJxVhm5+Udaj2O+cimBX3sOi1dsrZXwZAcUqG3gXMpBeoLnU8Y2AACkBbmUIcJUEyq2NzYqhJePJ81UZLmVmxu70DSNOVIx9w59agaWNRj5QapK7D5iT9KhuAZDuXrSHY1F+Zcg1YgJUgEZFZVp525c5wK1oJMNhhxTBlmPOc9RVqPII461XRwueOD0qwJtoGeKBFnblMhT9Kay9ug9KlgcEA7sZq2YgcZP40BczthwFxSqh3YGfrV2RNoHYVCxUjAPNAhmDux1FLtHPShcZIzTlA4FAyWGLcwA6V1XhjTvNnVwAcGsCHaAMV3fgaMv82OBTREmdvZw7IVGO1W1SliXCg1IBikyByAYp5AxTUHPFPbpSAgc/N0phNEh5NRk8cUwJlPI96cWwKrbwDQ0wx1osFyC9fCE5rifFe6SEgDIrrdRlCxnJ61yuryBUYtVWEnqcM8ZDcgg+tPkysa5NWw6SzHJ4zVfUUxwv3R3oNDKnbcTn7pqq3OccLVycHHtWfISGIGAKRSKs8RJyDmqpRielXj944pUQbdx4HakMqRJtckjgVFc3BZioJAAqa8cZCp3qg+eQDQA0sc/MePSms5IwMcVIygpnqaRowEYk0AYOoNiQ1hXUjK3U1tajjdkHvWDe8nOeM0maRIxOw705Crt82B3zVcEZ5pNwyeBUmluxYKg5200DqfSmo2eBUij3yPSgByEleenWp4iMk81GqZFSRxbmAzQiWXIXyeK0YRuXORmqMUKZGScitGBVUg+1NEEgJ2j27VetGOQWwKgWDdgpUiKynpTQmbtlLjjIxU09x8w5+lZNqzFh6VNcBg3HSmSdJpEx2E8V0mhsrTrk9TXFaPIwVgeprq9AyJgH6igmRyWpyDeQpA5rOWTOQSaikuN8hLc1G0ihsDvQNku8546UjSZ4BxUPm4JI6VFJJg57UBYtpKTwcGnrKQc9BWek/PBokuBg9qAsaqyqo3E5pkt3gfLgViJdFiQDxUfmMJDRcdi5IwYlmJz3qs77iACcZpy5YHHU06GE45xmgYKcrj9aRU+fOacUKdaRFIYnrSAewB4PSkji3A+1PjXPpT9pzhTTsFyzbMoXnG7pUc0iBsluajwY1J6E1QnbvnmhgkbMU25eCPxqykhbA4rChYhQQcfWrkEzbsfyoBo3bYjeo6etb2FFuGOcVzVhIHnA966W7kAtEUelMllGabfwOgqqThs5GfSnFySVVTUbjC8jmkMkiUsxz1q1HEWbjg1Sgfa2SDurc0iNZHDEgn0pibNDSdNM5G4HrXovhmzW1TGMVh6OuXTCgZrrrKMoozTMpO7NZOV4qVRxmq0TDHrVhDmpYDhTjSAUHqKQFeReTULjg1bkHNVZVpgUpWOfaqV3cPEBgZq+4znNUbqPcpz2qkScpr2uvG23bjFc1fau118pJxVzxRMpnZcdO9cu5Vf8aLmkUiwkzCTI+7VqWYSBVzWUHy38quBGyrDFBTG3KAISxyKypApfrk1pahMEgOMZrnZbgljt9e1JjRac7eTgD2qtcXHG1Tx6VA0u7qaic5b60hjmfOck5qNiPc00sFpoYY75oAmAyCOwolZdh4pqkg9OtMuGwCeKAOf1AjeeOKwL44PFbd6xMjHisK9BJxSZpDcplhmkzk8U1jz7Ug4+lQbE6sR0p4cg56GoUORk0M5oFYsicgcH8adHMfU1U3cU9DgZouDRpRXB9eav210d4DVixt0J61bhbHPrTTIaOmtL4Lya0redJFJFctA+cdhWtaybEGDxVXM2jpbJYmIYfLVqaEAbjzWTYSMQOeK1POYqFzke1NEmjpKI0gUr1rrtKth5oPvXI6fKomTdxXdaQAzgjpQRI8PSXBOaYZSxz1FVd5JPpU0Jw2D0oRfUlDEHqcU1245PFSEgVVkyzf1oBCMwBzmoZpDjilkCrgc5oUDYTxmgZBG5UnFWomLDOORTUQKSSBVlSPLyoApASR4Ubqkjk+b2qFTkdRS7cd+KYWJnbL4wMUAkc4qF2JcAVMAQvXigLEbsy8gVLE+Bn161C7ADmiPBQnNFwsSXRLLweKqqit1PSrnBjOOmKz2k2ucCgZOwCqBipLd8AgdarBy4GalgY7uvFIGaumOyyhiOldEZmeFdxrn7JwCO9aZkPQkCqJLG7LDb+Zp7D0OaiTjGBkVNjPTg0ARohJ5HFdF4bti8oY52+lZVrE0kgUjiu00azMQUnhcUImTOj0uJI8EDmt6NiQO30rFtFJYYrXh4A61VjEvRHBwBgVcjI21TiqynSpZRPk5PTHalpqmlpAI+Mc1XkIx1qWXO2qUpbPFCAgmPNU52+RgatyVQueBzVIlnn3jC3YZkRT+FcS05Bw5II7V6lrmGhYbc5FeWarFtun7c9KGaw2LUbAqDnNWzNiA7eMVi20204yDWkr74SBSKMm8ndt4Y/nWU8hB4q3fkrMcHn3qiQGJz19qGAqyZPHQ+tPdwAMdai2hRuHSmsSRSGOdxnnNNQ5bNBUkZ9akijUAUASZG05qKZgykYFPmZeQvWq2DhiT0oAwr44Zs1iXeTnkVt3g/eHOaybtOD06UmaRMsDmlxinN8ucUxcnrjFRY2F78UEcU7+Id/akPOcfpQFwUY61IAAODTfTinBcUCHrjA9asxN0xnNVk5OasxjGG5oQmaEJwtaNsTnnp71l2+WbmtCAnJ3Yx2qkZM37FuBWipAGc4rEsJMEd/StIMSw3VSJe5qWch8we3Ir0Hw9MTGmea8ztZf3n8hXoHhRjIoDHihkSPDEkbODV2NwrKWHFVQRyMc0hlI4xx70FM0JJAUOBVePPfkVEkpY/wBKsJggDHNIYh5IyMgUso2qMDrUyrgYPGahn4H0oAQj9171Fv8ALHBzT1kDKajcgjGBQA6N9x4PSpxuLCqsIIJIFXUKkADrQMkj9WxSs/cnjtVZ2O7ap471KoLKAcZpiGnDE5qFZgh2k8VPznbx9agkt/mzSGSS3HyYFV8kcmkKENjvTtm4ZPpQIFZmIx2q3EuBnHNVoBiSro6cCgZe04Fn6dKvkFnP5VBp0e2MtxV1VXPA6mqJJ7ckBVzxVoDgH9KihTEe4CrcKZUHOKBF3Rxm6TceCa9Gs4h5C4A6V57pUYFymfWvRdPyIlB9KZnMu2seOe9aUQzgVWgHGQKuwqd2R0pkFhBjAqynSq681Yj6VIyUCl5oWnGkMjYZqrMMVcbpVOY88c00BAy5FUbwAqRir7NwcVSufummiWcxqceUYY4rzXX1VLlueteh+IbhooZPL6+teVarNJLM2/qaGaQKJk2sdhGD1q7Z3J2gNjBrKkI8wL0x1xUobJAU8DvUlk2oovmE9jVFkCjI5PfNajKHi3Ecis6TLHHagCqZBjb+tM3ZwV705o/n6UFeMBTmgY9cYBB+op29R6UwqFAx1pAc4LCgBGO5/wBaeFXb060gx2p+CRgUAYOooQ7E9KxbkEg11Wpxbo9wGa5y6Tk0MqLMVs5OcZpvQAd6nnTa5GPeoiPSoNk7oTtQMA9TRn60D3pDQ8Z7c0oz2pF7/pToz0HegB68DnnvVlBkcdKgUDGSPwqdSeNoxTQmWrckd6uKemOQKpR9PertsAGwRmmZs09NDE5bvWoinOSM+lUtPAAIrTUAYHJNUiGFtxKM13PhO4KSqDjn3rioz84x2rqvD4/eKR1oYmeUnbjOearSHB4qSNMnFMdCjAdqQMI3OcY5rTsFLLlsfjWaGGfetGzlOMU0MuuDtGAPeq0q4BHHrzVosB14qvMQ27AzQCKUf3yMfjSrEc89KjLlGOT3q3CQynAOaQDUXD9OKeoAfPQ1KkeASaVYwTntTGMCgvnGak44xxUqRkE0pjBBzmgVyDcFNMJDHdTZuQR1xUDSFB060gJZXWmFxsHpTDhgTxTtmVA45oGOgYHPHPrVy3BJBPSqsER6Y5rTs0yRwMCmJkwdkUKvT27VoWzHAOear+UrfX2rRtbcRqN3U0yS7bjdF2q1HHjGKhg2xKAOhqYydAnU0CNPSrZ5rkNHnaDXoenW/wAqBhXK+E0BPPeu9tVUKKaM5MsRRgKOKsovFMjqwg45oZKADHSpkHemKKkWkMkXp706kWlpAMfoapSn5jirr8A81UYDJNNAQMCcVTuskHFXpDxVKdsg00By2tRjaS6jFeXa+gS4YhcCvXtXjEkJ9q8r8UxKkjNuP0oZUDkXA3kg4+tPiyWxxj1NRM2ZDn1qxEpOCMYqTQ0IBlMEnNV7mMDJWp7f0FTMqlcGgDFcDPPGKjOMc5+laFzabslO9VPszg/MvSgZA3OCOlD4AyO9SFdpwQQKAgbsaBECHJ5qfIx8vXFAjwBjrSEHcORQAjpuUqRzWDeWx8w1vM3AB6mq11ECSQAaBo46/h2knHNZzjHauou7cMW4rAuo9j4qWjaLuUwfnxTu/Sl245oUEkg1JYDPanrgN1NN4Hc04Dkdc0ASx5Ldasrx64qCNTnmp1zxzTJZPEc896u25wR6mqUeF6datwkqc9+1G5J0Wm48sliKvrjfz0rL0xiyHNXQ+cr61aM2W0YK/HU103h9vmXJ9q4+PIbOPaul0IncCSOvAoJZ5iHKrxmoJnZmHXFSoOtMkU44pFdSPncMZNatmMIvqKgtIdy5cVeUBVIFMNxxmO8huRSrIM9sVQuXII61ZsVeUg44pAOngDvwPerFtEAo4xVpYgOvWlVMZyKYrkbJuwAcZpwjEQwRUoXABAHvTJJMjAwPrQABSenHvQVP8ZqMSAZyaHmBXGfwoAqTrhvl79ap3GOpJrVKnbwBn1NU5oixIIpDKMTNzjpVuFvkwTzUkNtxtHSp4rQJJ+8IxQDI7VS0m0A4rWRPLXC5HrUECqpwmB71bRfMAHfvVCJ7RQGVmPFaIJYjmqSKF4APNTxjC8ZoEWYhhuTxViKQGQAj2GKoojtkkkD0rV0m03zIGOfamDO68KWziEMRxXZwIAMVleH4QsCADjFb0agEcUzDcliXGKnUCmRjAqZRSYwxTl4FIRTlFIBw6Up4opCaQDJTxVc8damfk+1MI4oArTDC1mT/AHjzya1ZxkVReLLciqQGVfJ+4I715H42JSYp7165rM621u5PpXi/iCaS6vndjkZOKGVA55ISeSR7VciQBDnpT4o+verCW7McYwKk0EhXajE012BHvVmaPbHtBAPrWbOxQECgZMJ9ucnFBu071mOx5JNVJrkgYoBI3jLbSdfxqMrCThG4rmJLpgTg063u3VuKYWOgeMADBzUEow1Zr3j8bSfehbyTOSaQWNBoznPWomiY8ioft54BAqYXox8w4oCxTuIeGORj0rmdUi/edO1dqGimBxjNYeq2oJbaBnFBUWck6jNORc9KsXEDIxyOKjj44PSosa3G7OeaPYCrLAEDFMCY55oC40Bse1SYwaEU96fswff3oC4+JTkE1eiAzyarQ9RV+zj8x1z0oRLNO0bZCF45qcFu1MVVGBmnKcNjPFWRuWoCDx3rqtAjAKs5AUHJzXIwOFYEjIFb+myNK6Bm2p6UE2PN2ZscCp4QeMioGLEgGplk244pIplsYWPAqRCSCc8elVxIDipwm4YBHSmIZsDS8nIrUt4yi/LVVbY4BrQhOxRnGO9AmG7cRnvUxUHGDmk2KeRTlCheOtAgkQBQeh9KzZ3YyEAVdupSqEYGfWsW6kcOfmoY1qTlcnLtgVYgWPeAzE+9Y29mPXirKMcYBoKZ0CBHIA6dKiuNkfYDPrUGnybRl+cVWu8yy5JNFyUiVbraCFUVGzyzNkDHsKjOQo4AxVq3dQRgYzQNotWkeB84q5D8hJ9aqKTnOeKsAnHPXHFMll5WOAe9WoVYr061mwOW4JrXt38uLLdvWgQ6MchRjNdNotozzoy8EDtXOQYLKcdTXoXhqz3wRuODTQpM6jR4yka5rajUY5qlZxbABWlGOKGZIeq048KTQBxTwMigY1OVyRTwPSgD2p1SAnekYU6kNAEbCmsKfTWpgQOPWqlwQF4q3JwCaoztnOaaBnF+L5XEJ5PtXm8sJlclyK9M8Xxh7dto5Jrg1gG/BFDLhsZa2h80ccVZMYHHPFXnjC5wOBUMiYUmkUUZ1G0/1rHuhyeK1LxiBWVPye9DGjJvJMfKtZdwxPf8KvXYZXJFUpIyeT37UikikhJYg1ZhAA3MeadHEAxzxSEcnFIdgEgB6GmFmBBpWRuOtO2cDHWgLCK/HJpwZz06UpjweBn607BUjAz9KLhYfHIyglSKheckndyamRTzkAVQnYiQ0xEF0A+celUJrfGCOlW3YgkqTjvSbg20Gkyk2imMBetPQE9+DT5ogrZHSoVl+bB4xUl7lhU6E0pUE89aUOu0DNOXBODTFcWIDIxWrbgRqGP4YqjCi5qVpOig0JCZe8/ByASaliSSZwWOB6VSicAjdxV+3mAHXimJloKFYKuSK3dLI3qT0HSucjkJmBByK3dGOZhk80yWcD0amOG3eoqZep/z3pR0P0qUa8g23YswHStO1j+bINZ1t96tiz6U7kuBOpYfLjPvU6qCPamjofpUkPSi4cg5Pk6ninZ4JByfelm+6KjHQUyeRFa4lLMVKgGs+dBy3ers/wDrqrP/ABUmUoGcUcnKjjNX7eIhQepqEdfxq/b9aVw5R0OFOG60TYbLdKVvv1HP9yqDkIUJZiB0qaFefmzSw/0qUdaA5Bhcq2ATViKdiMGoD96pIvvD60XFyGpZyDAB6mr17OkcIweT71StvvCn6l0WncXIi3ZzEqhJ7+teveD2LWScdq8btf8AVrXs3gj/AI8ovpTuTOmddbLkDmrq/WmWlW16UrmfsyMUbqmHQUd6A5CMHilJqYdKWkHIVi3NBORUzdaUdKA5CtTWqz3ppouHIUZMGqFwo5rVlqjdfcNNMTicR4nkCRsM4zXHy5JLgda6rxZ1Nc0v3R9aLlqFiOJHkfBAwaW7ttigjHJrSi7fSoL/AP1ZpXHyHH6iGEpXkCqEikZz0PatfUP9fVGX71FzRQMaW28xjjFVmiCcHGRW2/U/Ss24/ioGolAxFzwKaIMDkZq8v3KZQHIUZIj06Um3g4xVuXrUI70D5SAJgEnpTY246VPL9yoB1pByEq9Ko3S8k1pL90/Ss+470w5DNkHPXioJOoxVxupqtN0qblKIsbbuvWobmE5yBQn3hU8v3B9KGx8pQUMDjJq3CDwSSKjHennoKEFiVpdg4NRLMWkODxUUv3TTbfrRcFBGlE7OeTV+EscADpWbB95frWrbdaLicBRKwcdc+1dBoTnzVzn61z4/1w+tdFov+sX60XJ5D//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hysterosalpingogram on a 29-year-old woman with infertility demonstrates occlusion of both fallopian tubes (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_28_40399=[""].join("\n");
var outline_f39_28_40399=null;
